,ID,Description,GeneRatio,BgRatio,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-1799339,R-HSA-1799339,SRP-dependent cotranslational protein targeting to membrane,46/249,108/8183,3.76306169910442e-42,2.90508363170861e-39,2.42420395773885e-39,RPL37/SEC61G/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/SSR4/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/SPCS1/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/SEC11C/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPN1/RPS14/RPS17/DDOST/RPL22L1,46
R-HSA-156902,R-HSA-156902,Peptide chain elongation,41/249,85/8183,2.29448723171645e-40,8.85672071442552e-38,7.39066413584458e-38,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/EEF2/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,41
R-HSA-156842,R-HSA-156842,Eukaryotic Translation Elongation,41/249,89/8183,2.60124852774193e-39,6.69387954472257e-37,5.58583894378267e-37,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/EEF2/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,41
R-HSA-192823,R-HSA-192823,Viral mRNA Translation,40/249,85/8183,7.90383660496953e-39,1.52544046475912e-36,1.27293368480036e-36,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-156827,R-HSA-156827,L13a-mediated translational silencing of Ceruloplasmin expression,43/249,107/8183,4.59093020484294e-38,7.0883962362775e-36,5.91505112708185e-36,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/EIF4A2/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/EIF3L/RPL28/RPLP0/RPL26/EIF4A1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,43
R-HSA-72706,R-HSA-72706,GTP hydrolysis and joining of the 60S ribosomal subunit,43/249,108/8183,7.43805838939999e-38,7.93766225916805e-36,6.62373780012387e-36,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/EIF4A2/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/EIF3L/RPL28/RPLP0/RPL26/EIF4A1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,43
R-HSA-2408557,R-HSA-2408557,Selenocysteine synthesis,40/249,89/8183,8.22555674525187e-38,7.93766225916805e-36,6.62373780012387e-36,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-72764,R-HSA-72764,Eukaryotic Translation Termination,40/249,89/8183,8.22555674525187e-38,7.93766225916805e-36,6.62373780012387e-36,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-72689,R-HSA-72689,Formation of a pool of free 40S subunits,41/249,97/8183,2.15995797280968e-37,1.85276395001008e-35,1.54607518053745e-35,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/EIF3L/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,41
R-HSA-975956,R-HSA-975956,Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),40/249,91/8183,2.51053926559553e-37,1.93813631303975e-35,1.61731582162575e-35,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-72613,R-HSA-72613,Eukaryotic Translation Initiation,43/249,115/8183,1.85413633299543e-36,1.19282770756039e-34,9.95378452450179e-35,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/EIF4A2/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/EIF3L/RPL28/RPLP0/RPL26/EIF4A1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,43
R-HSA-72737,R-HSA-72737,Cap-dependent Translation Initiation,43/249,115/8183,1.85413633299543e-36,1.19282770756039e-34,9.95378452450179e-35,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/EIF4A2/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/EIF3L/RPL28/RPLP0/RPL26/EIF4A1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,43
R-HSA-168255,R-HSA-168255,Influenza Life Cycle,44/249,139/8183,1.17399972427237e-33,6.97175220875592e-32,5.8177152328315e-32,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/CALR/RPL29/RPL24/RPL14/HSPA1A/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/HSPA1B/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/POLR2H/RPL22L1,44
R-HSA-168254,R-HSA-168254,Influenza Infection,45/249,149/8183,2.1042143413575e-33,1.16032390823428e-31,9.68255020233679e-32,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/CALR/RPL29/RPL24/RPL14/HSPA1A/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/HSPA1B/SLC25A6/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/POLR2H/RPL22L1,45
R-HSA-927802,R-HSA-927802,Nonsense-Mediated Decay (NMD),40/249,111/8183,3.58373366973337e-33,1.72915149564635e-31,1.44292434597159e-31,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-975957,R-HSA-975957,Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),40/249,111/8183,3.58373366973337e-33,1.72915149564635e-31,1.44292434597159e-31,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-2408522,R-HSA-2408522,Selenoamino acid metabolism,40/249,113/8183,8.19942823617326e-33,3.72350505783868e-31,3.10715175265513e-31,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-9010553,R-HSA-9010553,Regulation of expression of SLITs and ROBOs,45/249,162/8183,1.27122717579706e-31,5.45215210952963e-30,4.54965515548423e-30,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/PSMB9/RPLP2/PSMB8/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RBX1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/PSMD7/PSMD6/RPS14/RPS17/RPL22L1,45
R-HSA-168273,R-HSA-168273,Influenza Viral RNA Transcription and Replication,41/249,129/8183,1.89655677769962e-31,7.70600964412688e-30,6.43043073657711e-30,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/POLR2H/RPL22L1,41
R-HSA-376176,R-HSA-376176,Signaling by ROBO receptors,49/249,205/8183,4.51303881622931e-31,1.74203298306451e-29,1.45367355554334e-29,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RHOA/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/PFN2/PSMB9/RPLP2/PSMB8/CDC42/RPS2/RAC1/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RBX1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/PSMD7/PSMD6/RPS14/RPS17/RPL22L1,49
R-HSA-72766,R-HSA-72766,Translation,52/249,287/8183,9.69823114380238e-27,3.56525449667402e-25,2.97509647118148e-25,RPL37/SEC61G/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/EIF4A2/RPL14/SSR4/RPS10/RPL36/EEF2/RPS18/RPL34/RPL39/RPL32/RPS19/SPCS1/RPSA/RPL27/RPLP2/RPS2/MRPL33/RPL27A/RPL35/MRPS24/RPL41/RPL35A/EIF3L/RPL28/SEC11C/RPLP0/RPL26/EIF4A1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPN1/RPS14/RPS17/DDOST/RPL22L1,52
R-HSA-5663205,R-HSA-5663205,Infectious disease,56/249,362/8183,3.36797289256098e-25,1.18185230593504e-23,9.86219813515465e-24,B2M/RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/CALR/RPL29/RPL24/RPL14/HSPA1A/CD9/RPS10/RPL36/EEF2/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/HSPA1B/SLC25A6/PSMB9/RPLP2/PSMB8/RPS2/RAC1/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RBX1/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/PSMD7/PSMD6/RPS14/RPS17/POLR2H/AP2M1/SYT1/RPL22L1,56
R-HSA-6791226,R-HSA-6791226,Major pathway of rRNA processing in the nucleolus and cytosol,40/249,179/8183,3.50989152022379e-24,1.17810271896207e-22,9.83090897197695e-23,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-8868773,R-HSA-8868773,rRNA processing in the nucleus and cytosol,40/249,189/8183,3.12685337490485e-23,1.00580450226106e-21,8.39313274316566e-22,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-422475,R-HSA-422475,Axon guidance,62/249,498/8183,1.02478140111964e-22,3.16452496665746e-21,2.64069986309567e-21,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/TUBB2B/RPL38/RHOA/RPS28/RPL36A/RPL15/RPL3/CD24/RPL29/RPL24/RPL14/TUBA1A/RPS10/RPL36/TUBB2A/RPS18/RPL34/TUBB3/RPL39/RPL32/RPS19/RPSA/RPL27/PFN2/PSMB9/RPLP2/PSMB8/CDC42/RPS2/RAC1/RPL27A/RHOB/RET/RPL35/RPL41/RPL35A/RPL28/MYL6/RPLP0/RPL26/RBX1/RPS16/RPLP1/ALCAM/RPS4Y1/RPS23/RPS5/PSMD7/PSMD6/RPS14/RPS17/DPYSL3/AP2M1/NCSTN/RPL22L1/TUBB4B,62
R-HSA-72312,R-HSA-72312,rRNA processing,40/249,198/8183,1.98206460516944e-22,5.88520721227234e-21,4.91102647110809e-21,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/RPL27/RPLP2/RPS2/RPL27A/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/RPS14/RPS17/RPL22L1,40
R-HSA-71291,R-HSA-71291,Metabolism of amino acids and derivatives,49/249,320/8183,8.22080316633651e-22,2.35054075718955e-20,1.9614547905645e-20,RPL37/RPL37A/RPS29/RPL13/RPS27/RPS21/RPL38/RPS28/RPL36A/RPL15/RPL3/RPL29/RPL24/RPL14/RPS10/RPL36/RPS18/RPL34/RPL39/RPL32/RPS19/RPSA/TPH1/RPL27/PSMB9/RPLP2/PSMB8/RPS2/RPL27A/OAZ1/PCBD1/RPL35/RPL41/RPL35A/RPL28/RPLP0/RPL26/RPS16/RPLP1/RPS4Y1/RPS23/RPS5/PSMD7/PSMD6/RPS14/PDHB/RPS17/ODC1/RPL22L1,49
R-HSA-72649,R-HSA-72649,Translation initiation complex formation,18/249,57/8183,2.91931447569859e-14,7.77141646634245e-13,6.4850107409348e-13,RPS29/RPS27/RPS21/RPS28/EIF4A2/RPS10/RPS18/RPS19/RPSA/RPS2/EIF3L/EIF4A1/RPS16/RPS4Y1/RPS23/RPS5/RPS14/RPS17,18
R-HSA-72702,R-HSA-72702,Ribosomal scanning and start codon recognition,18/249,57/8183,2.91931447569859e-14,7.77141646634245e-13,6.4850107409348e-13,RPS29/RPS27/RPS21/RPS28/EIF4A2/RPS10/RPS18/RPS19/RPSA/RPS2/EIF3L/EIF4A1/RPS16/RPS4Y1/RPS23/RPS5/RPS14/RPS17,18
R-HSA-72662,R-HSA-72662,Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S,18/249,58/8183,4.1193943618512e-14,1.06005748244971e-12,8.84585736650152e-13,RPS29/RPS27/RPS21/RPS28/EIF4A2/RPS10/RPS18/RPS19/RPSA/RPS2/EIF3L/EIF4A1/RPS16/RPS4Y1/RPS23/RPS5/RPS14/RPS17,18
R-HSA-72695,R-HSA-72695,Formation of the ternary complex, and subsequently, the 43S complex,16/249,50/8183,6.53814158676373e-13,1.62820816289729e-11,1.35869020410846e-11,RPS29/RPS27/RPS21/RPS28/RPS10/RPS18/RPS19/RPSA/RPS2/EIF3L/RPS16/RPS4Y1/RPS23/RPS5/RPS14/RPS17,16
R-HSA-6798695,R-HSA-6798695,Neutrophil degranulation,37/249,379/8183,1.98633693987294e-10,4.79203786744347e-09,3.99880989211263e-09,HLA-C/HLA-B/B2M/FABP5/RHOA/HSPA1A/NPC2/VAMP8/EEF2/CD63/PSAP/FTH1/MME/DPP7/HSPA1B/GRN/MIF/HSPA6/CSTB/RAC1/DSP/SVIP/APRT/GGH/PSMD7/LAMP1/HEXB/PSMD6/CD47/RAB7A/NME2/NCSTN/DDOST/DYNLL1/ALDOA/CYBA/TUBB4B,37
R-HSA-1236975,R-HSA-1236975,Antigen processing-Cross presentation,14/249,89/8183,4.03660857383309e-07,9.44321763333075e-06,7.88007798145407e-06,HLA-C/HLA-B/B2M/HLA-A/PDIA3/SEC61G/CALR/VAMP8/PSMB9/PSMB8/PSMD7/PSMD6/CTSL/CYBA,14
R-HSA-1236974,R-HSA-1236974,ER-Phagosome pathway,12/249,78/8183,3.52848124770106e-06,8.01172800948594e-05,6.68554341669675e-05,HLA-C/HLA-B/B2M/HLA-A/PDIA3/SEC61G/CALR/VAMP8/PSMB9/PSMB8/PSMD7/PSMD6,12
R-HSA-389977,R-HSA-389977,Post-chaperonin tubulin folding pathway,6/249,16/8183,4.63291500947103e-06,0.000102188868208904,8.52735033322187e-05,TUBB2B/TUBA1A/TUBB2A/TUBB3/TBCD/TUBB4B,6
R-HSA-8953897,R-HSA-8953897,Cellular responses to external stimuli,33/249,470/8183,5.11090625652698e-06,0.000109600545278856,9.14583224852196e-05,TUBB2B/HSPA1A/TUBA1A/CA9/TOMM7/TUBB2A/TUBB3/TERF2IP/HIST1H4C/HIST1H1C/HSPA1B/HIST1H2AC/FOS/GABARAPL2/PSMB9/PSMB8/HSPA6/HSBP1/HSPA5/SNCB/CDKN1A/MAP1LC3B/RBX1/GABARAP/PSMD7/PSMD6/CAMK2B/JUN/DYNLL1/CYBA/MT1F/DNAJB1/TUBB4B,33
R-HSA-163200,R-HSA-163200,Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.,14/249,110/8183,5.49395615870226e-06,0.000114630652824815,9.56557942852286e-05,ATP5F1E/NDUFB1/COX4I1/NDUFAF3/NDUFB4/ATP5ME/NDUFA3/NDUFB5/UQCR11/UQCR10/COX6C/UQCRC1/NDUFA6/NDUFS5,14
R-HSA-1428517,R-HSA-1428517,The citric acid (TCA) cycle and respiratory electron transport,17/249,158/8183,5.64281942791422e-06,0.00011463833153552,9.5662201935831e-05,BSG/ATP5F1E/NDUFB1/COX4I1/NDUFAF3/NDUFB4/ATP5ME/NDUFA3/MDH2/NDUFB5/UQCR11/UQCR10/COX6C/PDHB/UQCRC1/NDUFA6/NDUFS5,17
R-HSA-983170,R-HSA-983170,Antigen Presentation: Folding, assembly and peptide loading of class I MHC,7/249,25/8183,6.67564381451384e-06,0.00013214351345653,0.000110269743980633,HLA-C/HLA-B/B2M/HLA-A/PDIA3/CALR/HSPA5,7
R-HSA-3371497,R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR),9/249,46/8183,7.96362494273733e-06,0.000153697961394831,0.000128256275393559,TUBB2B/HSPA1A/TUBA1A/TUBB2A/TUBB3/HSPA1B/DYNLL1/DNAJB1/TUBB4B,9
R-HSA-5626467,R-HSA-5626467,RHO GTPases activate IQGAPs,7/249,26/8183,8.8999177596492e-06,0.000167578939279248,0.000139839529368557,TUBB2B/TUBA1A/TUBB2A/TUBB3/CDC42/RAC1/TUBB4B,7
R-HSA-1236977,R-HSA-1236977,Endosomal/Vacuolar pathway,5/249,11/8183,9.96681501178125e-06,0.000183199552121312,0.000152874455819803,HLA-C/HLA-B/B2M/HLA-A/CTSL,5
R-HSA-611105,R-HSA-611105,Respiratory electron transport,12/249,90/8183,1.60958388258479e-05,0.000285859068570989,0.000238540700798262,NDUFB1/COX4I1/NDUFAF3/NDUFB4/NDUFA3/NDUFB5/UQCR11/UQCR10/COX6C/UQCRC1/NDUFA6/NDUFS5,12
R-HSA-190840,R-HSA-190840,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,5/249,12/8183,1.66627695410551e-05,0.000285859068570989,0.000238540700798262,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-190872,R-HSA-190872,Transport of connexons to the plasma membrane,5/249,12/8183,1.66627695410551e-05,0.000285859068570989,0.000238540700798262,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-2262752,R-HSA-2262752,Cellular responses to stress,27/249,378/8183,2.92799412593811e-05,0.000491393796787875,0.000410053181939159,TUBB2B/HSPA1A/TUBA1A/CA9/TUBB2A/TUBB3/TERF2IP/HIST1H4C/HIST1H1C/HSPA1B/HIST1H2AC/FOS/PSMB9/PSMB8/HSPA6/HSBP1/HSPA5/CDKN1A/RBX1/PSMD7/PSMD6/CAMK2B/JUN/DYNLL1/CYBA/DNAJB1/TUBB4B,27
R-HSA-8852276,R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,10/249,69/8183,3.97768839520651e-05,0.000653356476829666,0.000545206113743871,TUBB2B/TUBA1A/TUBB2A/TUBB3/PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6/TUBB4B,10
R-HSA-1445148,R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,9/249,64/8183,0.000123461201684487,0.0019856676604255,0.00165697928576549,TUBB2B/TUBA1A/RAB13/TUBB2A/TUBB3/RAC1/YWHAH/YWHAG/TUBB4B,9
R-HSA-5663220,R-HSA-5663220,RHO GTPases Activate Formins,13/249,131/8183,0.000166841411198102,0.00262860345805989,0.00219348965957548,RPS27/TUBB2B/RHOA/TUBA1A/TUBB2A/TUBB3/PFN2/CDC42/RAC1/MAD1L1/RHOB/DYNLL1/TUBB4B,13
R-HSA-76002,R-HSA-76002,Platelet activation, signaling and aggregation,17/249,207/8183,0.000182384953831008,0.00281602368715077,0.0023498861419911,TIMP1/RHOA/TAGLN2/CD9/LGALS3BP/CD63/PSAP/GNG2/CDC42/HGF/RAC1/HSPA5/RHOB/MANF/GNB2/CHID1/ALDOA,17
R-HSA-190828,R-HSA-190828,Gap junction trafficking,6/249,29/8183,0.000196996098197231,0.00298198015310318,0.00248837176670186,TUBB2B/TUBA1A/TUBB2A/TUBB3/AP2M1/TUBB4B,6
R-HSA-190861,R-HSA-190861,Gap junction assembly,5/249,19/8183,0.000205344892721833,0.00299106145625009,0.00249594983804889,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-389960,R-HSA-389960,Formation of tubulin folding intermediates by CCT/TriC,5/249,19/8183,0.000205344892721833,0.00299106145625009,0.00249594983804889,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-114608,R-HSA-114608,Platelet degranulation ,11/249,103/8183,0.000279053931955954,0.00398943769388882,0.00332906445140436,TIMP1/TAGLN2/CD9/LGALS3BP/CD63/PSAP/HGF/HSPA5/MANF/CHID1/ALDOA,11
R-HSA-157858,R-HSA-157858,Gap junction trafficking and regulation,6/249,31/8183,0.000290154709558014,0.00399998992462119,0.00333786996709595,TUBB2B/TUBA1A/TUBB2A/TUBB3/AP2M1/TUBB4B,6
R-HSA-9609736,R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,6/249,31/8183,0.000290154709558014,0.00399998992462119,0.00333786996709595,TUBB2B/TUBA1A/TUBB2A/TUBB3/CAMK2B/TUBB4B,6
R-HSA-76005,R-HSA-76005,Response to elevated platelet cytosolic Ca2+,11/249,106/8183,0.000358945530078122,0.00486150788105808,0.00405678050614609,TIMP1/TAGLN2/CD9/LGALS3BP/CD63/PSAP/HGF/HSPA5/MANF/CHID1/ALDOA,11
R-HSA-9619483,R-HSA-9619483,Activation of AMPK downstream of NMDARs,5/249,22/8183,0.000431536524935548,0.0057438999525904,0.00479310985953821,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-195258,R-HSA-195258,RHO GTPase Effectors,20/249,291/8183,0.00054240349822841,0.00709721187512429,0.0059224075096483,RPS27/TUBB2B/RHOA/TUBA1A/TUBB2A/TUBB3/HIST1H4C/BRK1/HIST1H2AC/PFN2/CDC42/RAC1/MAD1L1/RHOB/MYL6/YWHAH/YWHAG/DYNLL1/CYBA/TUBB4B,20
R-HSA-6799198,R-HSA-6799198,Complex I biogenesis,7/249,49/8183,0.000639666748666171,0.00812069847428251,0.00677647595617793,NDUFB1/NDUFAF3/NDUFB4/NDUFA3/NDUFB5/NDUFA6/NDUFS5,7
R-HSA-3371568,R-HSA-3371568,Attenuation phase,4/249,14/8183,0.000658406988923862,0.00812069847428251,0.00677647595617793,HSPA1A/HSPA1B/HSBP1/DNAJB1,4
R-HSA-3371571,R-HSA-3371571,HSF1-dependent transactivation,5/249,24/8183,0.00066269948689093,0.00812069847428251,0.00677647595617793,HSPA1A/HSPA1B/HSBP1/CAMK2B/DNAJB1,5
R-HSA-389957,R-HSA-389957,Prefoldin mediated transfer of substrate  to CCT/TriC,5/249,24/8183,0.00066269948689093,0.00812069847428251,0.00677647595617793,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-5358351,R-HSA-5358351,Signaling by Hedgehog,12/249,134/8183,0.000758112184148064,0.00914472822128602,0.00763099764306933,TUBB2B/TUBA1A/EVC2/TUBB2A/TUBB3/OS9/PSMB9/PSMB8/RBX1/PSMD7/PSMD6/TUBB4B,12
R-HSA-389958,R-HSA-389958,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,5/249,26/8183,0.000975883149119553,0.0115904890941584,0.00967191072487719,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-5610787,R-HSA-5610787,Hedgehog 'off' state,10/249,102/8183,0.0010350924734813,0.0121074452958721,0.0101032949564682,TUBB2B/TUBA1A/TUBB2A/TUBB3/PSMB9/PSMB8/RBX1/PSMD7/PSMD6/TUBB4B,10
R-HSA-437239,R-HSA-437239,Recycling pathway of L1,6/249,40/8183,0.0012031155741488,0.0138627645260131,0.0115680554812108,TUBB2B/TUBA1A/TUBB2A/TUBB3/AP2M1/TUBB4B,6
R-HSA-391251,R-HSA-391251,Protein folding,9/249,88/8183,0.00135914088340392,0.015430246499821,0.0128760715269845,TUBB2B/TUBA1A/RGS7/TUBB2A/TUBB3/GNG2/TBCD/GNB2/TUBB4B,9
R-HSA-109582,R-HSA-109582,Hemostasis,26/249,461/8183,0.00166383747742703,0.0186156888778792,0.0155342263338725,TIMP1/TUBB2B/RHOA/BSG/TAGLN2/EPCAM/TUBA1A/CD9/LGALS3BP/TUBB2A/CD63/PSAP/TUBB3/GNG2/MIF/CDC42/HGF/RAC1/HSPA5/RHOB/MANF/GNB2/CD47/CHID1/ALDOA/TUBB4B,26
R-HSA-6811436,R-HSA-6811436,COPI-independent Golgi-to-ER retrograde traffic,6/249,43/8183,0.00177093992170736,0.0195309374222583,0.0162979734148106,TUBB2B/TUBA1A/TUBB2A/TUBB3/DYNLL1/TUBB4B,6
R-HSA-5625740,R-HSA-5625740,RHO GTPases activate PKNs,8/249,75/8183,0.00190443953890506,0.0207074270990804,0.0172797182773891,RHOA/HIST1H4C/HIST1H2AC/RAC1/RHOB/MYL6/YWHAH/YWHAG,8
R-HSA-8955332,R-HSA-8955332,Carboxyterminal post-translational modifications of tubulin,5/249,32/8183,0.00257485651097495,0.0276081837010092,0.0230381898350391,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-5625900,R-HSA-5625900,RHO GTPases activate CIT,4/249,20/8183,0.00276003438363406,0.0291883088241848,0.0243567562045284,RHOA/RAC1/RHOB/MYL6,4
R-HSA-381183,R-HSA-381183,ATF6 (ATF6-alpha) activates chaperone genes,3/249,10/8183,0.00285038399977239,0.029736438484112,0.0248141537391281,HSP90B1/CALR/HSPA5,3
R-HSA-5687128,R-HSA-5687128,MAPK6/MAPK4 signaling,8/249,81/8183,0.00310608310426666,0.0319719487532514,0.0266796190850694,PSMB9/PSMB8/CDC42/RAC1/PSMD7/PSMD6/JUN/DNAJB1,8
R-HSA-373760,R-HSA-373760,L1CAM interactions,9/249,100/8183,0.00330162466948412,0.0335375558531808,0.0279860706055995,TUBB2B/CD24/TUBA1A/TUBB2A/TUBB3/RAC1/ALCAM/AP2M1/TUBB4B,9
R-HSA-390466,R-HSA-390466,Chaperonin-mediated protein folding,8/249,82/8183,0.00335360940230381,0.0336232007607603,0.0280575386768275,TUBB2B/TUBA1A/RGS7/TUBB2A/TUBB3/GNG2/GNB2/TUBB4B,8
R-HSA-350562,R-HSA-350562,Regulation of ornithine decarboxylase (ODC),6/249,49/8183,0.00349025247014806,0.0345445500891578,0.0288263766765265,PSMB9/PSMB8/OAZ1/PSMD7/PSMD6/ODC1,6
R-HSA-5625970,R-HSA-5625970,RHO GTPases activate KTN1,3/249,11/8183,0.00383178635158839,0.0373199850400257,0.031142392752244,RHOA/CDC42/RAC1,3
R-HSA-5620924,R-HSA-5620924,Intraflagellar transport,6/249,50/8183,0.00386735596269696,0.0373199850400257,0.031142392752244,TUBB2B/TUBA1A/TUBB2A/TUBB3/DYNLL1/TUBB4B,6
R-HSA-438064,R-HSA-438064,Post NMDA receptor activation events,7/249,68/8183,0.00442718277199009,0.0421948777774858,0.0352103425140732,TUBB2B/TUBA1A/TUBB2A/TUBB3/RAC1/CAMK2B/TUBB4B,7
R-HSA-69275,R-HSA-69275,G2/M Transition,13/249,187/8183,0.00456791825272572,0.043005279159808,0.0358865978262919,TUBB2B/TUBA1A/TUBB2A/TUBB3/PSMB9/PSMB8/CDKN1A/RBX1/PSMD7/PSMD6/YWHAG/DYNLL1/TUBB4B,13
R-HSA-453274,R-HSA-453274,Mitotic G2-G2/M phases,13/249,189/8183,0.00499498352432996,0.0453678975428204,0.0378581310283694,TUBB2B/TUBA1A/TUBB2A/TUBB3/PSMB9/PSMB8/CDKN1A/RBX1/PSMD7/PSMD6/YWHAG/DYNLL1/TUBB4B,13
R-HSA-381033,R-HSA-381033,ATF6 (ATF6-alpha) activates chaperones,3/249,12/8183,0.00499517006624318,0.0453678975428204,0.0378581310283694,HSP90B1/CALR/HSPA5,3
R-HSA-381771,R-HSA-381771,Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1),3/249,12/8183,0.00499517006624318,0.0453678975428204,0.0378581310283694,GRP/SPCS1/SEC11C,3
R-HSA-2132295,R-HSA-2132295,MHC class II antigen presentation,9/249,107/8183,0.00518067971849631,0.0465056365427808,0.0388075396293726,TUBB2B/TUBA1A/TUBB2A/TUBB3/RAB7A/AP2M1/DYNLL1/CTSL/TUBB4B,9
R-HSA-397795,R-HSA-397795,G-protein beta:gamma signalling,4/249,24/8183,0.00550273885340608,0.0482740272139716,0.0402832078742168,RHOA/GNG2/CDC42/GNB2,4
R-HSA-400685,R-HSA-400685,Sema4D in semaphorin signaling,4/249,24/8183,0.00550273885340608,0.0482740272139716,0.0402832078742168,RHOA/RAC1/RHOB/MYL6,4
R-HSA-450408,R-HSA-450408,AUF1 (hnRNP D0) binds and destabilizes mRNA,6/249,54/8183,0.00568294742767742,0.0492947799344603,0.041134994982124,HSPA1A/HSPA1B/PSMB9/PSMB8/PSMD7/PSMD6,6
R-HSA-6785807,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,7/249,72/8183,0.00607257077560064,0.0520891626529299,0.043466822393773,TIMP1/HSP90B1/FSCN1/FOS/HGF/CDKN1A/JUNB,7
R-HSA-3000480,R-HSA-3000480,Scavenging by Class A Receptors,3/249,13/8183,0.00634920006579857,0.0532780701173532,0.0444589295225254,HSP90B1/CALR/FTH1,3
R-HSA-400508,R-HSA-400508,Incretin synthesis, secretion, and inactivation,3/249,13/8183,0.00634920006579857,0.0532780701173532,0.0444589295225254,GRP/SPCS1/SEC11C,3
R-HSA-112314,R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,11/249,155/8183,0.00757552400755943,0.0628849949874826,0.0524756162153522,TUBB2B/TUBA1A/TUBB2A/TUBB3/GNG2/RAC1/GRIK2/GNB2/CAMK2B/AP2M1/TUBB4B,11
R-HSA-442755,R-HSA-442755,Activation of NMDA receptors and postsynaptic events,7/249,76/8183,0.00813665165528484,0.0668244157221266,0.0557629430350988,TUBB2B/TUBA1A/TUBB2A/TUBB3/RAC1/CAMK2B/TUBB4B,7
R-HSA-2467813,R-HSA-2467813,Separation of Sister Chromatids,12/249,181/8183,0.00912021227016318,0.0741137249743787,0.0618456499649847,RPS27/TUBB2B/TUBA1A/TUBB2A/TUBB3/PSMB9/PSMB8/MAD1L1/PSMD7/PSMD6/DYNLL1/TUBB4B,12
R-HSA-114604,R-HSA-114604,GPVI-mediated activation cascade,4/249,28/8183,0.00964268805277721,0.0775432830910834,0.0647075119331102,RHOA/CDC42/RAC1/RHOB,4
R-HSA-112315,R-HSA-112315,Transmission across Chemical Synapses,13/249,208/8183,0.0108631845240503,0.0864575098202769,0.072146163089732,TUBB2B/TUBA1A/TUBB2A/TUBB3/GNG2/RAC1/CACNA2D1/GRIK2/GNB2/CAMK2B/AP2M1/SYT1/TUBB4B,13
R-HSA-8964616,R-HSA-8964616,G beta:gamma signalling through CDC42,3/249,16/8183,0.011622746099997,0.0915587753999766,0.0764030141052437,GNG2/CDC42/GNB2,3
R-HSA-162909,R-HSA-162909,Host Interactions of HIV factors,9/249,122/8183,0.0119150643952756,0.0929134314459875,0.0775334333855254,B2M/SLC25A6/PSMB9/PSMB8/RAC1/RBX1/PSMD7/PSMD6/AP2M1,9
R-HSA-499943,R-HSA-499943,Interconversion of nucleotide di- and triphosphates,4/249,30/8183,0.0123098899454406,0.0950323503788015,0.0793016068064174,NME1/NME4/NME2/CTPS1,4
R-HSA-68882,R-HSA-68882,Mitotic Anaphase,12/249,192/8183,0.014129095121786,0.107996647861572,0.0901199188591248,RPS27/TUBB2B/TUBA1A/TUBB2A/TUBB3/PSMB9/PSMB8/MAD1L1/PSMD7/PSMD6/DYNLL1/TUBB4B,12
R-HSA-2555396,R-HSA-2555396,Mitotic Metaphase and Anaphase,12/249,193/8183,0.0146716630087147,0.111044351399292,0.0926631347918825,RPS27/TUBB2B/TUBA1A/TUBB2A/TUBB3/PSMB9/PSMB8/MAD1L1/PSMD7/PSMD6/DYNLL1/TUBB4B,12
R-HSA-4086400,R-HSA-4086400,PCP/CE pathway,7/249,86/8183,0.0155038745062781,0.116203797270356,0.0969685354914889,RHOA/PSMB9/PSMB8/RAC1/PSMD7/PSMD6/AP2M1,7
R-HSA-3371556,R-HSA-3371556,Cellular response to heat stress,7/249,87/8183,0.0164379127993446,0.122019891164365,0.101821888999989,HSPA1A/HSPA1B/HSPA6/HSBP1/HSPA5/CAMK2B/DNAJB1,7
R-HSA-380320,R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,7/249,88/8183,0.017411151371015,0.126843189958498,0.105846785184893,TUBB2B/TUBA1A/TUBB2A/TUBB3/YWHAG/DYNLL1/TUBB4B,7
R-HSA-983189,R-HSA-983189,Kinesins,5/249,50/8183,0.0174162929217627,0.126843189958498,0.105846785184893,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-5683057,R-HSA-5683057,MAPK family signaling cascades,14/249,246/8183,0.0178908449598136,0.129081610364263,0.107714678951362,PSMB9/PSMB8/CDC42/HGF/RAC1/RET/RBX1/DUSP1/PSMD7/PSMD6/CAMK2B/JUN/DNAJB1/DUSP2,14
R-HSA-3858494,R-HSA-3858494,Beta-catenin independent WNT signaling,9/249,131/8183,0.0182796430547747,0.130665596650797,0.10903646734427,RHOA/GNG2/PSMB9/PSMB8/RAC1/PSMD7/PSMD6/GNB2/AP2M1,9
R-HSA-392451,R-HSA-392451,G beta:gamma signalling through PI3Kgamma,3/249,19/8183,0.0188083821256787,0.133211660559853,0.111161080259926,RHOA/GNG2/GNB2,3
R-HSA-180585,R-HSA-180585,Vif-mediated degradation of APOBEC3G,5/249,52/8183,0.0203484137958322,0.139443925766919,0.116361716074931,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-8854050,R-HSA-8854050,FBXL7 down-regulates AURKA during mitotic entry and in early mitosis,5/249,52/8183,0.0203484137958322,0.139443925766919,0.116361716074931,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-909733,R-HSA-909733,Interferon alpha/beta signaling,5/249,52/8183,0.0203484137958322,0.139443925766919,0.116361716074931,HLA-C/HLA-B/HLA-A/EGR1/PSMB8,5
R-HSA-6807878,R-HSA-6807878,COPI-mediated anterograde transport,7/249,91/8183,0.0205738726301061,0.139443925766919,0.116361716074931,TUBB2B/TUBA1A/TUBB2A/TUBB3/FOLR1/DYNLL1/TUBB4B,7
R-HSA-1234174,R-HSA-1234174,Cellular response to hypoxia,6/249,71/8183,0.0205914605407108,0.139443925766919,0.116361716074931,CA9/PSMB9/PSMB8/RBX1/PSMD7/PSMD6,6
R-HSA-5627117,R-HSA-5627117,RHO GTPases Activate ROCKs,3/249,20/8183,0.0216404434919219,0.145273238050119,0.121226099927288,RHOA/RHOB/MYL6,3
R-HSA-5362768,R-HSA-5362768,Hh mutants that don't undergo autocatalytic processing are degraded by ERAD,5/249,53/8183,0.0219284259022956,0.14528878872576,0.121239076493271,OS9/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-194315,R-HSA-194315,Signaling by Rho GTPases,20/249,405/8183,0.0220191558042926,0.14528878872576,0.121239076493271,RPS27/TUBB2B/RHOA/TUBA1A/TUBB2A/TUBB3/HIST1H4C/BRK1/HIST1H2AC/PFN2/CDC42/RAC1/MAD1L1/RHOB/MYL6/YWHAH/YWHAG/DYNLL1/CYBA/TUBB4B,20
R-HSA-4641258,R-HSA-4641258,Degradation of DVL,5/249,54/8183,0.0235861277874607,0.15301252648672,0.127684300804298,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-9604323,R-HSA-9604323,Negative regulation of NOTCH4 signaling,5/249,54/8183,0.0235861277874607,0.15301252648672,0.127684300804298,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-416572,R-HSA-416572,Sema4D induced cell migration and growth-cone collapse,3/249,21/8183,0.0246923484065839,0.157541264213907,0.131463394735357,RHOA/RHOB/MYL6,3
R-HSA-9609523,R-HSA-9609523,Insertion of tail-anchored proteins into the endoplasmic reticulum membrane,3/249,21/8183,0.0246923484065839,0.157541264213907,0.131463394735357,SEC61G/CYB5A/SERP1,3
R-HSA-5387390,R-HSA-5387390,Hh mutants abrogate ligand secretion,5/249,55/8183,0.0253227076513663,0.160238773007007,0.133714383801865,OS9/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-5610780,R-HSA-5610780,Degradation of GLI1 by the proteasome,5/249,56/8183,0.0271392695255625,0.167612128589874,0.13986722483911,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-5610783,R-HSA-5610783,Degradation of GLI2 by the proteasome,5/249,56/8183,0.0271392695255625,0.167612128589874,0.13986722483911,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-5610785,R-HSA-5610785,GLI3 is processed to GLI3R by the proteasome,5/249,56/8183,0.0271392695255625,0.167612128589874,0.13986722483911,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-5632684,R-HSA-5632684,Hedgehog 'on' state,6/249,76/8183,0.0277598788702439,0.170084337204986,0.141930207757638,EVC2/PSMB9/PSMB8/RBX1/PSMD7/PSMD6,6
R-HSA-157118,R-HSA-157118,Signaling by NOTCH,12/249,212/8183,0.0282773379608714,0.17148403428656,0.143098212412564,MDK/HIST1H4C/HIST1H2AC/PSMB9/YBX1/PSMB8/DLK1/RBX1/PSMD7/PSMD6/JUN/NCSTN,12
R-HSA-2500257,R-HSA-2500257,Resolution of Sister Chromatid Cohesion,8/249,119/8183,0.0284325859956991,0.17148403428656,0.143098212412564,RPS27/TUBB2B/TUBA1A/TUBB2A/TUBB3/MAD1L1/DYNLL1/TUBB4B,8
R-HSA-164952,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,3/249,23/8183,0.0314540068389081,0.187465090303893,0.156433917733819,B2M/RAC1/AP2M1,3
R-HSA-449147,R-HSA-449147,Signaling by Interleukins,17/249,342/8183,0.0315679556211219,0.187465090303893,0.156433917733819,TIMP1/HSP90B1/FSCN1/FOS/MIF/PSMB9/PSMB8/CDC42/HGF/CDKN1A/RPLP0/RBX1/IL17RB/PSMD7/PSMD6/JUN/JUNB,17
R-HSA-351202,R-HSA-351202,Metabolism of polyamines,6/249,79/8183,0.0327667763591718,0.192209179735797,0.16039271611441,PSMB9/PSMB8/OAZ1/PSMD7/PSMD6/ODC1,6
R-HSA-5678895,R-HSA-5678895,Defective CFTR causes cystic fibrosis,5/249,59/8183,0.0330786054976927,0.192209179735797,0.16039271611441,OS9/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-983169,R-HSA-983169,Class I MHC mediated antigen processing & presentation,17/249,344/8183,0.0331137576487838,0.192209179735797,0.16039271611441,HLA-C/HLA-B/B2M/HLA-A/PDIA3/SEC61G/CALR/VAMP8/PSMB9/PSMB8/HSPA5/MYLIP/RBX1/PSMD7/PSMD6/CTSL/CYBA,17
R-HSA-5627123,R-HSA-5627123,RHO GTPases activate PAKs,3/249,24/8183,0.0351613308368369,0.197610036963193,0.164899567250442,CDC42/RAC1/MYL6,3
R-HSA-187577,R-HSA-187577,SCF(Skp2)-mediated degradation of p27/p21,5/249,60/8183,0.0352244218983341,0.197610036963193,0.164899567250442,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-111367,R-HSA-111367,SLBP independent Processing of Histone Pre-mRNAs,2/249,10/8183,0.0353240739649231,0.197610036963193,0.164899567250442,SNRPF/SNRPE,2
R-HSA-2022377,R-HSA-2022377,Metabolism of Angiotensinogen to Angiotensins,2/249,10/8183,0.0353240739649231,0.197610036963193,0.164899567250442,CPB1/MME,2
R-HSA-450341,R-HSA-450341,Activation of the AP-1 family of transcription factors,2/249,10/8183,0.0353240739649231,0.197610036963193,0.164899567250442,FOS/JUN,2
R-HSA-2980736,R-HSA-2980736,Peptide hormone metabolism,5/249,61/8183,0.037454450488315,0.206534541264137,0.172346794728186,CPB1/GRP/SPCS1/MME/SEC11C,5
R-HSA-5358346,R-HSA-5358346,Hedgehog ligand biogenesis,5/249,61/8183,0.037454450488315,0.206534541264137,0.172346794728186,OS9/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-8854214,R-HSA-8854214,TBC/RABGAPs,4/249,42/8183,0.0379360376539283,0.207706532403069,0.173324785697679,GABARAPL2/MAP1LC3B/GABARAP/RAB7A,4
R-HSA-9013694,R-HSA-9013694,Signaling by NOTCH4,6/249,82/8183,0.0383268848022334,0.208368697657213,0.173877342468249,PSMB9/PSMB8/RBX1/PSMD7/PSMD6/NCSTN,6
R-HSA-1234176,R-HSA-1234176,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,5/249,63/8183,0.0421693993883113,0.222264367334296,0.185472856297504,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-2559586,R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,5/249,63/8183,0.0421693993883113,0.222264367334296,0.185472856297504,TERF2IP/HIST1H4C/HIST1H1C/HIST1H2AC/CDKN1A,5
R-HSA-373755,R-HSA-373755,Semaphorin interactions,5/249,63/8183,0.0421693993883113,0.222264367334296,0.185472856297504,RHOA/RAC1/RHOB/MYL6/DPYSL3,5
R-HSA-77588,R-HSA-77588,SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,2/249,11/8183,0.0423223601012196,0.222264367334296,0.185472856297504,SNRPF/SNRPE,2
R-HSA-8875555,R-HSA-8875555,MET activates RAP1 and RAC1,2/249,11/8183,0.0423223601012196,0.222264367334296,0.185472856297504,HGF/RAC1,2
R-HSA-901042,R-HSA-901042,Calnexin/calreticulin cycle,3/249,26/8183,0.0432186732639812,0.225437944322929,0.188121109797699,PDIA3/CALR/OS9,3
R-HSA-69563,R-HSA-69563,p53-Dependent G1 DNA Damage Response,5/249,64/8183,0.0446552306681048,0.229825587171846,0.191782464343019,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-69580,R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,5/249,64/8183,0.0446552306681048,0.229825587171846,0.191782464343019,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-450531,R-HSA-450531,Regulation of mRNA stability by proteins that bind AU-rich elements,6/249,86/8183,0.0466269529382097,0.238296201857208,0.198850934737676,HSPA1A/HSPA1B/PSMB9/PSMB8/PSMD7/PSMD6,6
R-HSA-1236978,R-HSA-1236978,Cross-presentation of soluble exogenous antigens (endosomes),4/249,45/8183,0.0470943283002794,0.238296201857208,0.198850934737676,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-5658442,R-HSA-5658442,Regulation of RAS by GAPs,5/249,65/8183,0.047227097000198,0.238296201857208,0.198850934737676,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-70263,R-HSA-70263,Gluconeogenesis,3/249,27/8183,0.0475630863645711,0.238433134243174,0.198965200650154,PGAM2/MDH2/ALDOA,3
R-HSA-2682334,R-HSA-2682334,EPH-Ephrin signaling,6/249,87/8183,0.0488631781336811,0.240696281150793,0.200853727930577,RHOA/CDC42/RAC1/MYL6/AP2M1/NCSTN,6
R-HSA-418885,R-HSA-418885,DCC mediated attractive signaling,2/249,12/8183,0.049787798108215,0.240696281150793,0.200853727930577,CDC42/RAC1,2
R-HSA-422085,R-HSA-422085,Synthesis, secretion, and deacylation of Ghrelin,2/249,12/8183,0.049787798108215,0.240696281150793,0.200853727930577,SPCS1/SEC11C,2
R-HSA-5660526,R-HSA-5660526,Response to metal ions,2/249,12/8183,0.049787798108215,0.240696281150793,0.200853727930577,SNCB/MT1F,2
R-HSA-8866427,R-HSA-8866427,VLDLR internalisation and degradation,2/249,12/8183,0.049787798108215,0.240696281150793,0.200853727930577,MYLIP/AP2M1,2
R-HSA-69615,R-HSA-69615,G1/S DNA Damage Checkpoints,5/249,66/8183,0.0498852396167447,0.240696281150793,0.200853727930577,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-3371453,R-HSA-3371453,Regulation of HSF1-mediated heat shock response,5/249,67/8183,0.0526298154176815,0.2523615993941,0.21058808130514,HSPA1A/HSPA1B/HSPA6/HSPA5/DNAJB1,5
R-HSA-110328,R-HSA-110328,Recognition and association of DNA glycosylase with site containing an affected pyrimidine,4/249,47/8183,0.0538223979754311,0.253359092908736,0.21142045931299,TERF2IP/HIST1H4C/HIST1H2AC/NTHL1,4
R-HSA-110329,R-HSA-110329,Cleavage of the damaged pyrimidine ,4/249,47/8183,0.0538223979754311,0.253359092908736,0.21142045931299,TERF2IP/HIST1H4C/HIST1H2AC/NTHL1,4
R-HSA-73928,R-HSA-73928,Depyrimidination,4/249,47/8183,0.0538223979754311,0.253359092908736,0.21142045931299,TERF2IP/HIST1H4C/HIST1H2AC/NTHL1,4
R-HSA-8939902,R-HSA-8939902,Regulation of RUNX2 expression and activity,5/249,68/8183,0.0554608979496063,0.25948977707331,0.21653632883674,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-114452,R-HSA-114452,Activation of BH3-only proteins,3/249,29/8183,0.0568661906994253,0.259767451005659,0.216768039290242,YWHAH/YWHAG/DYNLL1,3
R-HSA-451326,R-HSA-451326,Activation of kainate receptors upon glutamate binding,3/249,29/8183,0.0568661906994253,0.259767451005659,0.216768039290242,GNG2/GRIK2/GNB2,3
R-HSA-5339562,R-HSA-5339562,Uptake and actions of bacterial toxins,3/249,29/8183,0.0568661906994253,0.259767451005659,0.216768039290242,CD9/EEF2/SYT1,3
R-HSA-8964043,R-HSA-8964043,Plasma lipoprotein clearance,3/249,29/8183,0.0568661906994253,0.259767451005659,0.216768039290242,NPC2/MYLIP/AP2M1,3
R-HSA-211733,R-HSA-211733,Regulation of activated PAK-2p34 by proteasome mediated degradation,4/249,48/8183,0.05737183150513,0.260429121165578,0.217320182919735,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-75035,R-HSA-75035,Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,2/249,13/8183,0.0576857250250179,0.260429121165578,0.217320182919735,YWHAH/YWHAG,2
R-HSA-68949,R-HSA-68949,Orc1 removal from chromatin,5/249,69/8183,0.0583784785129862,0.262024333790845,0.218651339350964,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-913531,R-HSA-913531,Interferon Signaling,9/249,162/8183,0.0587440116095916,0.262140907298293,0.218748616398357,HLA-C/HLA-B/B2M/HLA-A/EIF4A2/EGR1/PSMB8/EIF4A1/CAMK2B,9
R-HSA-109581,R-HSA-109581,Apoptosis,9/249,163/8183,0.0606061531189007,0.266606925612467,0.222475372886323,HIST1H1C/PSMB9/PSMB8/DSP/YWHAH/PSMD7/PSMD6/YWHAG/DYNLL1,9
R-HSA-180534,R-HSA-180534,Vpu mediated degradation of CD4,4/249,49/8183,0.0610438699299544,0.266606925612467,0.222475372886323,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-73929,R-HSA-73929,Base-Excision Repair, AP Site Formation,4/249,49/8183,0.0610438699299544,0.266606925612467,0.222475372886323,TERF2IP/HIST1H4C/HIST1H2AC/NTHL1,4
R-HSA-5619084,R-HSA-5619084,ABC transporter disorders,5/249,70/8183,0.0613824673894433,0.266606925612467,0.222475372886323,OS9/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-2173782,R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,3/249,30/8183,0.0618168907832014,0.266606925612467,0.222475372886323,HSP90B1/CALR/FTH1,3
R-HSA-2871796,R-HSA-2871796,FCERI mediated MAPK activation,3/249,30/8183,0.0618168907832014,0.266606925612467,0.222475372886323,FOS/RAC1/JUN,3
R-HSA-877300,R-HSA-877300,Interferon gamma signaling,5/249,71/8183,0.0644726951810139,0.270565436751332,0.225778630067924,HLA-C/HLA-B/B2M/HLA-A/CAMK2B,5
R-HSA-349425,R-HSA-349425,Autodegradation of the E3 ubiquitin ligase COP1,4/249,50/8183,0.0648375722784927,0.270565436751332,0.225778630067924,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-69601,R-HSA-69601,Ubiquitin Mediated Degradation of Phosphorylated Cdc25A,4/249,50/8183,0.0648375722784927,0.270565436751332,0.225778630067924,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-69610,R-HSA-69610,p53-Independent DNA Damage Response,4/249,50/8183,0.0648375722784927,0.270565436751332,0.225778630067924,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-69613,R-HSA-69613,p53-Independent G1/S DNA damage checkpoint,4/249,50/8183,0.0648375722784927,0.270565436751332,0.225778630067924,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-75815,R-HSA-75815,Ubiquitin-dependent degradation of Cyclin D,4/249,50/8183,0.0648375722784927,0.270565436751332,0.225778630067924,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-8849471,R-HSA-8849471,PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases,2/249,14/8183,0.0659831401056359,0.272400984821128,0.227310339119894,RHOA/RAC1,2
R-HSA-8964315,R-HSA-8964315,G beta:gamma signalling through BTK,2/249,14/8183,0.0659831401056359,0.272400984821128,0.227310339119894,GNG2/GNB2,2
R-HSA-5357801,R-HSA-5357801,Programmed Cell Death,9/249,166/8183,0.0664181743733401,0.272738460724567,0.227591952499911,HIST1H1C/PSMB9/PSMB8/DSP/YWHAH/PSMD7/PSMD6/YWHAG/DYNLL1,9
R-HSA-169911,R-HSA-169911,Regulation of Apoptosis,4/249,51/8183,0.06875184903974,0.27934753165178,0.233107021231101,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-1474228,R-HSA-1474228,Degradation of the extracellular matrix,6/249,95/8183,0.069113184644417,0.27934753165178,0.233107021231101,TIMP1/BSG/ELN/CAPN2/NCSTN/CTSL,6
R-HSA-5689603,R-HSA-5689603,UCH proteinases,6/249,95/8183,0.069113184644417,0.27934753165178,0.233107021231101,UCHL1/HIST1H2AC/PSMB9/PSMB8/PSMD7/PSMD6,6
R-HSA-8950505,R-HSA-8950505,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,3/249,32/8183,0.0722942744617869,0.290683228565102,0.242566315628364,MIF/CDC42/RPLP0,3
R-HSA-72165,R-HSA-72165,mRNA Splicing - Minor Pathway,4/249,52/8183,0.072785468643399,0.291141874573596,0.242949041776712,SNRPF/YBX1/SNRPE/POLR2H,4
R-HSA-111447,R-HSA-111447,Activation of BAD and translocation to mitochondria ,2/249,15/8183,0.0746486364168423,0.292531712252803,0.244108819060152,YWHAH/YWHAG,2
R-HSA-163210,R-HSA-163210,Formation of ATP by chemiosmotic coupling,2/249,15/8183,0.0746486364168423,0.292531712252803,0.244108819060152,ATP5F1E/ATP5ME,2
R-HSA-392851,R-HSA-392851,Prostacyclin signalling through prostacyclin receptor,2/249,15/8183,0.0746486364168423,0.292531712252803,0.244108819060152,GNG2/GNB2,2
R-HSA-430039,R-HSA-430039,mRNA decay by 5' to 3' exoribonuclease,2/249,15/8183,0.0746486364168423,0.292531712252803,0.244108819060152,LSM3/LSM5,2
R-HSA-174113,R-HSA-174113,SCF-beta-TrCP mediated degradation of Emi1,4/249,53/8183,0.0769370639692035,0.298469413991081,0.249063650617046,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-4641257,R-HSA-4641257,Degradation of AXIN,4/249,53/8183,0.0769370639692035,0.298469413991081,0.249063650617046,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-195721,R-HSA-195721,Signaling by WNT,13/249,276/8183,0.0781449306558951,0.301639432331755,0.251708934533725,RHOA/SOX4/HIST1H4C/GNG2/HIST1H2AC/PSMB9/PSMB8/RAC1/RBX1/PSMD7/PSMD6/GNB2/AP2M1,13
R-HSA-2454202,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,7/249,124/8183,0.0836613276112836,0.32132609410901,0.268136855187775,FOS/PSMB9/PSMB8/RAC1/PSMD7/PSMD6/JUN,7
R-HSA-69541,R-HSA-69541,Stabilization of p53,4/249,55/8183,0.0855880746451056,0.325487653330155,0.271609549820091,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-8941858,R-HSA-8941858,Regulation of RUNX3 expression and activity,4/249,55/8183,0.0855880746451056,0.325487653330155,0.271609549820091,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-195253,R-HSA-195253,Degradation of beta-catenin by the destruction complex,5/249,78/8183,0.0884887260473142,0.330134499422683,0.275487201590785,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-73884,R-HSA-73884,Base Excision Repair,5/249,78/8183,0.0884887260473142,0.330134499422683,0.275487201590785,TERF2IP/HIST1H4C/HIST1H2AC/BPHL/NTHL1,5
R-HSA-983231,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,7/249,126/8183,0.0892991304484943,0.330134499422683,0.275487201590785,TUBB2B/TUBA1A/TUBB2A/TUBB3/CDC42/RAC1/TUBB4B,7
R-HSA-425397,R-HSA-425397,Transport of vitamins, nucleosides, and related molecules,3/249,35/8183,0.0893757906468144,0.330134499422683,0.275487201590785,APOD/SLC25A6/LCN15,3
R-HSA-532668,R-HSA-532668,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,3/249,35/8183,0.0893757906468144,0.330134499422683,0.275487201590785,PDIA3/CALR/OS9,3
R-HSA-5663213,R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,3/249,35/8183,0.0893757906468144,0.330134499422683,0.275487201590785,BRK1/CDC42/RAC1,3
R-HSA-429914,R-HSA-429914,Deadenylation-dependent mRNA decay,4/249,56/8183,0.0900841365773783,0.3311664449416,0.276348328748649,EIF4A2/EIF4A1/LSM3/LSM5,4
R-HSA-1296041,R-HSA-1296041,Activation of G protein gated Potassium channels,2/249,17/8183,0.0929658217378097,0.333812159914368,0.27855609744695,GNG2/GNB2,2
R-HSA-1296059,R-HSA-1296059,G protein gated Potassium channels,2/249,17/8183,0.0929658217378097,0.333812159914368,0.27855609744695,GNG2/GNB2,2
R-HSA-392170,R-HSA-392170,ADP signalling through P2Y purinoceptor 12,2/249,17/8183,0.0929658217378097,0.333812159914368,0.27855609744695,GNG2/GNB2,2
R-HSA-418217,R-HSA-418217,G beta:gamma signalling through PLC beta,2/249,17/8183,0.0929658217378097,0.333812159914368,0.27855609744695,GNG2/GNB2,2
R-HSA-997272,R-HSA-997272,Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits,2/249,17/8183,0.0929658217378097,0.333812159914368,0.27855609744695,GNG2/GNB2,2
R-HSA-5676590,R-HSA-5676590,NIK-->noncanonical NF-kB signaling,4/249,57/8183,0.0946914802986559,0.336874759403513,0.281111743598241,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-68827,R-HSA-68827,CDT1 association with the CDC6:ORC:origin complex,4/249,57/8183,0.0946914802986559,0.336874759403513,0.281111743598241,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-8957275,R-HSA-8957275,Post-translational protein phosphorylation,5/249,80/8183,0.0961001145352378,0.338763874069423,0.282688152345905,TIMP1/HSP90B1/CHGB/PDIA6/IGFBP5,5
R-HSA-977225,R-HSA-977225,Amyloid fiber formation,5/249,80/8183,0.0961001145352378,0.338763874069423,0.282688152345905,B2M/HIST1H4C/HIST1H2AC/NCSTN/NPPA,5
R-HSA-112316,R-HSA-112316,Neuronal System,14/249,314/8183,0.0976784697686124,0.342762630278949,0.286024992815267,TUBB2B/TUBA1A/TUBB2A/TUBB3/GNG2/RAC1/CACNA2D1/GRIK2/GNB2/SLITRK6/CAMK2B/AP2M1/SYT1/TUBB4B,14
R-HSA-5607761,R-HSA-5607761,Dectin-1 mediated noncanonical NF-kB signaling,4/249,58/8183,0.0994081581877388,0.347253837651287,0.289772768806364,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-6814122,R-HSA-6814122,Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,3/249,37/8183,0.101611257204847,0.347271624970731,0.289787611783594,RGS7/GNG2/GNB2,3
R-HSA-5673001,R-HSA-5673001,RAF/MAP kinase cascade,10/249,208/8183,0.10236704120626,0.347271624970731,0.289787611783594,PSMB9/PSMB8/HGF/RET/RBX1/DUSP1/PSMD7/PSMD6/CAMK2B/DUSP2,10
R-HSA-164938,R-HSA-164938,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,2/249,18/8183,0.102562086131252,0.347271624970731,0.289787611783594,B2M/AP2M1,2
R-HSA-418592,R-HSA-418592,ADP signalling through P2Y purinoceptor 1,2/249,18/8183,0.102562086131252,0.347271624970731,0.289787611783594,GNG2/GNB2,2
R-HSA-428930,R-HSA-428930,Thromboxane signalling through TP receptor,2/249,18/8183,0.102562086131252,0.347271624970731,0.289787611783594,GNG2/GNB2,2
R-HSA-500657,R-HSA-500657,Presynaptic function of Kainate receptors,2/249,18/8183,0.102562086131252,0.347271624970731,0.289787611783594,GNG2/GNB2,2
R-HSA-8964038,R-HSA-8964038,LDL clearance,2/249,18/8183,0.102562086131252,0.347271624970731,0.289787611783594,NPC2/AP2M1,2
R-HSA-8939236,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,6/249,107/8183,0.107326424736546,0.35977407011326,0.300220522101603,HIST1H4C/HIST1H2AC/PSMB9/PSMB8/PSMD7/PSMD6,6
R-HSA-171306,R-HSA-171306,Packaging Of Telomere Ends,3/249,38/8183,0.107966362528504,0.35977407011326,0.300220522101603,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-9020591,R-HSA-9020591,Interleukin-12 signaling,3/249,38/8183,0.107966362528504,0.35977407011326,0.300220522101603,MIF/CDC42/RPLP0,3
R-HSA-69202,R-HSA-69202,Cyclin E associated events during G1/S transition ,5/249,83/8183,0.10811863246927,0.35977407011326,0.300220522101603,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-8878166,R-HSA-8878166,Transcriptional regulation by RUNX2,6/249,108/8183,0.110923042723856,0.367521841127968,0.306685801432119,PSMB9/PSMB8/CDKN1A/RBX1/PSMD7/PSMD6,6
R-HSA-5668599,R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,2/249,19/8183,0.112415463073084,0.369296755286899,0.308166913329128,RAC1/CYBA,2
R-HSA-8876725,R-HSA-8876725,Protein methylation,2/249,19/8183,0.112415463073084,0.369296755286899,0.308166913329128,EEF2/RPS2,2
R-HSA-4608870,R-HSA-4608870,Asymmetric localization of PCP proteins,4/249,61/8183,0.114193303273425,0.373547585284254,0.311714101709795,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-5684996,R-HSA-5684996,MAPK1/MAPK3 signaling,10/249,213/8183,0.114840069358243,0.374078200609974,0.312156884065045,PSMB9/PSMB8/HGF/RET/RBX1/DUSP1/PSMD7/PSMD6/CAMK2B/DUSP2,10
R-HSA-69656,R-HSA-69656,Cyclin A:Cdk2-associated events at S phase entry,5/249,85/8183,0.116520393084337,0.377956905298775,0.315393545190688,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-1296065,R-HSA-1296065,Inwardly rectifying K+ channels,2/249,20/8183,0.12250157635988,0.392411688588496,0.327455622329097,GNG2/GNB2,2
R-HSA-8862803,R-HSA-8862803,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,2/249,20/8183,0.12250157635988,0.392411688588496,0.327455622329097,CAPN2/JUN,2
R-HSA-8863678,R-HSA-8863678,Neurodegenerative Diseases,2/249,20/8183,0.12250157635988,0.392411688588496,0.327455622329097,CAPN2/JUN,2
R-HSA-174084,R-HSA-174084,Autodegradation of Cdh1 by Cdh1:APC/C,4/249,63/8183,0.124556950375752,0.394090023320003,0.328856141630545,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-198933,R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,4/249,63/8183,0.124556950375752,0.394090023320003,0.328856141630545,HLA-C/HLA-B/B2M/HLA-A,4
R-HSA-373080,R-HSA-373080,Class B/2 (Secretin family receptors),4/249,63/8183,0.124556950375752,0.394090023320003,0.328856141630545,RAMP1/GNG2/GNB2/CALCB,4
R-HSA-381119,R-HSA-381119,Unfolded Protein Response (UPR),5/249,87/8183,0.125223316679426,0.394581226434764,0.329266035694131,HSP90B1/CALR/PDIA6/SERP1/HSPA5,5
R-HSA-3928662,R-HSA-3928662,EPHB-mediated forward signaling,3/249,41/8183,0.127910624789895,0.400209056004478,0.333962288348433,RHOA/CDC42/RAC1,3
R-HSA-69052,R-HSA-69052,Switching of origins to a post-replicative state,5/249,88/8183,0.129684688410381,0.400209056004478,0.333962288348433,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-1169091,R-HSA-1169091,Activation of NF-kappaB in B cells,4/249,64/8183,0.129883731689595,0.400209056004478,0.333962288348433,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-162906,R-HSA-162906,HIV Infection,10/249,219/8183,0.130887691273918,0.400209056004478,0.333962288348433,B2M/SLC25A6/PSMB9/PSMB8/RAC1/RBX1/PSMD7/PSMD6/POLR2H/AP2M1,10
R-HSA-112409,R-HSA-112409,RAF-independent MAPK1/3 activation,2/249,21/8183,0.13279728456549,0.400209056004478,0.333962288348433,DUSP1/DUSP2,2
R-HSA-202040,R-HSA-202040,G-protein activation,2/249,21/8183,0.13279728456549,0.400209056004478,0.333962288348433,GNG2/GNB2,2
R-HSA-5205685,R-HSA-5205685,Pink/Parkin Mediated Mitophagy,2/249,21/8183,0.13279728456549,0.400209056004478,0.333962288348433,TOMM7/MAP1LC3B,2
R-HSA-68877,R-HSA-68877,Mitotic Prometaphase,9/249,193/8183,0.134094746666428,0.400209056004478,0.333962288348433,RPS27/TUBB2B/TUBA1A/TUBB2A/TUBB3/MAD1L1/YWHAG/DYNLL1/TUBB4B,9
R-HSA-1632852,R-HSA-1632852,Macroautophagy,5/249,89/8183,0.134217627897506,0.400209056004478,0.333962288348433,TOMM7/GABARAPL2/MAP1LC3B/GABARAP/DYNLL1,5
R-HSA-2559582,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),5/249,89/8183,0.134217627897506,0.400209056004478,0.333962288348433,HIST1H4C/HIST1H2AC/FOS/CDKN1A/JUN,5
R-HSA-382556,R-HSA-382556,ABC-family proteins mediated transport,5/249,89/8183,0.134217627897506,0.400209056004478,0.333962288348433,OS9/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-6811434,R-HSA-6811434,COPI-dependent Golgi-to-ER retrograde traffic,5/249,89/8183,0.134217627897506,0.400209056004478,0.333962288348433,TUBB2B/TUBA1A/TUBB2A/TUBB3/TUBB4B,5
R-HSA-110330,R-HSA-110330,Recognition and association of DNA glycosylase with site containing an affected purine,3/249,42/8183,0.134831746877277,0.400209056004478,0.333962288348433,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-110331,R-HSA-110331,Cleavage of the damaged purine,3/249,42/8183,0.134831746877277,0.400209056004478,0.333962288348433,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-73927,R-HSA-73927,Depurination,3/249,42/8183,0.134831746877277,0.400209056004478,0.333962288348433,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-174154,R-HSA-174154,APC/C:Cdc20 mediated degradation of Securin,4/249,65/8183,0.135303838882343,0.400209056004478,0.333962288348433,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-9006931,R-HSA-9006931,Signaling by Nuclear Receptors,10/249,221/8183,0.136493539510729,0.4021870706194,0.335612881400427,TFF3/FABP5/HIST1H4C/GNG2/HIST1H2AC/FOS/PDHB/GNB2/POLR2H/JUN,10
R-HSA-199977,R-HSA-199977,ER to Golgi Anterograde Transport,7/249,141/8183,0.138120820218722,0.405434498892978,0.338322761552363,TUBB2B/TUBA1A/TUBB2A/TUBB3/FOLR1/DYNLL1/TUBB4B,7
R-HSA-15869,R-HSA-15869,Metabolism of nucleotides,5/249,90/8183,0.138820802613244,0.405774624362563,0.338606585914765,APRT/NME1/NME4/NME2/CTPS1,5
R-HSA-68867,R-HSA-68867,Assembly of the pre-replicative complex,4/249,66/8183,0.140814716254317,0.405774624362563,0.338606585914765,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-8948751,R-HSA-8948751,Regulation of PTEN stability and activity,4/249,66/8183,0.140814716254317,0.405774624362563,0.338606585914765,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-68886,R-HSA-68886,M Phase,15/249,364/8183,0.143166030880406,0.405774624362563,0.338606585914765,RPS27/TUBB2B/TUBA1A/TUBB2A/TUBB3/HIST1H4C/HIST1H2AC/PSMB9/PSMB8/MAD1L1/PSMD7/PSMD6/YWHAG/DYNLL1/TUBB4B,15
R-HSA-196071,R-HSA-196071,Metabolism of steroid hormones,2/249,22/8183,0.143280628962669,0.405774624362563,0.338606585914765,TSPO/AKR1B1,2
R-HSA-2979096,R-HSA-2979096,NOTCH2 Activation and Transmission of Signal to the Nucleus,2/249,22/8183,0.143280628962669,0.405774624362563,0.338606585914765,MDK/NCSTN,2
R-HSA-420092,R-HSA-420092,Glucagon-type ligand receptors,2/249,22/8183,0.143280628962669,0.405774624362563,0.338606585914765,GNG2/GNB2,2
R-HSA-77387,R-HSA-77387,Insulin receptor recycling,2/249,22/8183,0.143280628962669,0.405774624362563,0.338606585914765,ATP6AP1/ATP6V0E2,2
R-HSA-381426,R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5/249,91/8183,0.143492839962409,0.405774624362563,0.338606585914765,TIMP1/HSP90B1/CHGB/PDIA6/IGFBP5,5
R-HSA-4420097,R-HSA-4420097,VEGFA-VEGFR2 Pathway,5/249,91/8183,0.143492839962409,0.405774624362563,0.338606585914765,RHOA/BRK1/CDC42/RAC1/CYBA,5
R-HSA-416482,R-HSA-416482,G alpha (12/13) signalling events,4/249,67/8183,0.146413757577278,0.412523433757878,0.344238262148652,RHOA/GNG2/RHOB/GNB2,4
R-HSA-8878159,R-HSA-8878159,Transcriptional regulation by RUNX3,5/249,93/8183,0.153037824941634,0.429059172918797,0.358036833687352,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-392518,R-HSA-392518,Signal amplification,2/249,23/8183,0.153930783450647,0.429059172918797,0.358036833687352,GNG2/GNB2,2
R-HSA-446203,R-HSA-446203,Asparagine N-linked glycosylation,12/249,283/8183,0.153949988210501,0.429059172918797,0.358036833687352,PDIA3/TUBB2B/CALR/TUBA1A/TUBB2A/TUBB3/OS9/FOLR1/RPN1/DDOST/DYNLL1/TUBB4B,12
R-HSA-447115,R-HSA-447115,Interleukin-12 family signaling,3/249,45/8183,0.156329678254969,0.433825116049217,0.362013868314863,MIF/CDC42/RPLP0,3
R-HSA-380259,R-HSA-380259,Loss of Nlp from mitotic centrosomes,4/249,69/8183,0.157865685629609,0.433825116049217,0.362013868314863,TUBA1A/YWHAG/DYNLL1/TUBB4B,4
R-HSA-380284,R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,4/249,69/8183,0.157865685629609,0.433825116049217,0.362013868314863,TUBA1A/YWHAG/DYNLL1/TUBB4B,4
R-HSA-9020702,R-HSA-9020702,Interleukin-1 signaling,5/249,94/8183,0.157907846644857,0.433825116049217,0.362013868314863,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-8856688,R-HSA-8856688,Golgi-to-ER retrograde transport,6/249,121/8183,0.162977758967914,0.440034674577148,0.367195556096557,TUBB2B/TUBA1A/TUBB2A/TUBB3/DYNLL1/TUBB4B,6
R-HSA-174178,R-HSA-174178,APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,4/249,70/8183,0.16371315340174,0.440034674577148,0.367195556096557,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-174184,R-HSA-174184,Cdc20:Phospho-APC/C mediated degradation of Cyclin A,4/249,70/8183,0.16371315340174,0.440034674577148,0.367195556096557,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-69017,R-HSA-69017,CDK-mediated phosphorylation and removal of Cdc6,4/249,70/8183,0.16371315340174,0.440034674577148,0.367195556096557,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-2424491,R-HSA-2424491,DAP12 signaling,2/249,24/8183,0.164728006415539,0.440034674577148,0.367195556096557,B2M/RAC1,2
R-HSA-399719,R-HSA-399719,Trafficking of AMPA receptors,2/249,24/8183,0.164728006415539,0.440034674577148,0.367195556096557,CAMK2B/AP2M1,2
R-HSA-399721,R-HSA-399721,Glutamate binding, activation of AMPA receptors and synaptic plasticity,2/249,24/8183,0.164728006415539,0.440034674577148,0.367195556096557,CAMK2B/AP2M1,2
R-HSA-9013507,R-HSA-9013507,NOTCH3 Activation and Transmission of Signal to the Nucleus,2/249,24/8183,0.164728006415539,0.440034674577148,0.367195556096557,YBX1/NCSTN,2
R-HSA-179419,R-HSA-179419,APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint,4/249,71/8183,0.169637956877604,0.451587940377622,0.376836405114677,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-194138,R-HSA-194138,Signaling by VEGF,5/249,97/8183,0.17288981318405,0.458663009546691,0.382740335209401,RHOA/BRK1/CDC42/RAC1/CYBA,5
R-HSA-8854518,R-HSA-8854518,AURKA Activation by TPX2,4/249,72/8183,0.175637312326083,0.461240050740691,0.384890797727438,TUBA1A/YWHAG/DYNLL1/TUBB4B,4
R-HSA-400042,R-HSA-400042,Adrenaline,noradrenaline inhibits insulin secretion,2/249,25/8183,0.175653594453061,0.461240050740691,0.384890797727438,GNG2/GNB2,2
R-HSA-429947,R-HSA-429947,Deadenylation of mRNA,2/249,25/8183,0.175653594453061,0.461240050740691,0.384890797727438,EIF4A2/EIF4A1,2
R-HSA-109606,R-HSA-109606,Intrinsic Pathway for Apoptosis,3/249,48/8183,0.178802858277268,0.466337184425849,0.38914420080259,YWHAH/YWHAG/DYNLL1,3
R-HSA-3928665,R-HSA-3928665,EPH-ephrin mediated repulsion of cells,3/249,48/8183,0.178802858277268,0.466337184425849,0.38914420080259,RAC1/AP2M1/NCSTN,3
R-HSA-176409,R-HSA-176409,APC/C:Cdc20 mediated degradation of mitotic proteins,4/249,73/8183,0.181708414473922,0.472319515063527,0.394136273819033,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-174824,R-HSA-174824,Plasma lipoprotein assembly, remodeling, and clearance,3/249,49/8183,0.186482792299919,0.475658596856746,0.396922636046262,NPC2/MYLIP/AP2M1,3
R-HSA-381070,R-HSA-381070,IRE1alpha activates chaperones,3/249,49/8183,0.186482792299919,0.475658596856746,0.396922636046262,PDIA6/SERP1/HSPA5,3
R-HSA-1222556,R-HSA-1222556,ROS and RNS production in phagocytes,2/249,26/8183,0.186689837885484,0.475658596856746,0.396922636046262,ATP6V0E2/CYBA,2
R-HSA-3928663,R-HSA-3928663,EPHA-mediated growth cone collapse,2/249,26/8183,0.186689837885484,0.475658596856746,0.396922636046262,RHOA/MYL6,2
R-HSA-456926,R-HSA-456926,Thrombin signalling through proteinase activated receptors (PARs),2/249,26/8183,0.186689837885484,0.475658596856746,0.396922636046262,GNG2/GNB2,2
R-HSA-8949613,R-HSA-8949613,Cristae formation,2/249,26/8183,0.186689837885484,0.475658596856746,0.396922636046262,ATP5F1E/ATP5ME,2
R-HSA-176814,R-HSA-176814,Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,4/249,74/8183,0.187848440795343,0.477036172019751,0.39807218063279,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-9018519,R-HSA-9018519,Estrogen-dependent gene expression,6/249,127/8183,0.189999757682097,0.480917419444521,0.401310963594283,TFF3/HIST1H4C/HIST1H2AC/FOS/POLR2H/JUN,6
R-HSA-2871837,R-HSA-2871837,FCERI mediated NF-kB activation,4/249,75/8183,0.194054555644923,0.489575545613988,0.40853590662089,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-69481,R-HSA-69481,G2/M Checkpoints,7/249,156/8183,0.197399759374663,0.496392880251595,0.414224765085869,HIST1H4C/PSMB9/PSMB8/YWHAH/PSMD7/PSMD6/YWHAG,7
R-HSA-917937,R-HSA-917937,Iron uptake and transport,3/249,51/8183,0.202090851547687,0.50653940712602,0.422691733243966,FTH1/ATP6AP1/ATP6V0E2,3
R-HSA-416476,R-HSA-416476,G alpha (q) signalling events,6/249,131/8183,0.208913919167139,0.512284902058194,0.427486174065469,GRP/TAC3/GNG2/RGS2/GNRH2/GNB2,6
R-HSA-163359,R-HSA-163359,Glucagon signaling in metabolic regulation,2/249,28/8183,0.209028165995248,0.512284902058194,0.427486174065469,GNG2/GNB2,2
R-HSA-2172127,R-HSA-2172127,DAP12 interactions,2/249,28/8183,0.209028165995248,0.512284902058194,0.427486174065469,B2M/RAC1,2
R-HSA-5205647,R-HSA-5205647,Mitophagy,2/249,28/8183,0.209028165995248,0.512284902058194,0.427486174065469,TOMM7/MAP1LC3B,2
R-HSA-70268,R-HSA-70268,Pyruvate metabolism,2/249,28/8183,0.209028165995248,0.512284902058194,0.427486174065469,BSG/PDHB,2
R-HSA-75067,R-HSA-75067,Processing of Capped Intronless Pre-mRNA,2/249,28/8183,0.209028165995248,0.512284902058194,0.427486174065469,SNRPF/SNRPE,2
R-HSA-917977,R-HSA-917977,Transferrin endocytosis and recycling,2/249,28/8183,0.209028165995248,0.512284902058194,0.427486174065469,ATP6AP1/ATP6V0E2,2
R-HSA-71406,R-HSA-71406,Pyruvate metabolism and Citric Acid (TCA) cycle,3/249,52/8183,0.210007507643868,0.513056316142613,0.428129895663048,BSG/MDH2/PDHB,3
R-HSA-1474244,R-HSA-1474244,Extracellular matrix organization,9/249,216/8183,0.21204816000384,0.515572481274741,0.430229558958469,TIMP1/BSG/PPIB/MFAP2/ELN/CD47/CAPN2/NCSTN/CTSL,9
R-HSA-1168372,R-HSA-1168372,Downstream signaling events of B Cell Receptor (BCR),4/249,78/8183,0.213040960526739,0.515572481274741,0.430229558958469,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-176408,R-HSA-176408,Regulation of APC/C activators between G1/S and early anaphase,4/249,78/8183,0.213040960526739,0.515572481274741,0.430229558958469,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-168898,R-HSA-168898,Toll-like Receptor Cascades,6/249,133/8183,0.218614292970136,0.526536083231475,0.439378351428501,S100A1/HSP90B1/FOS/CNPY3/JUN/CTSL,6
R-HSA-2129379,R-HSA-2129379,Molecules associated with elastic fibres,2/249,29/8183,0.220299423424568,0.526536083231475,0.439378351428501,MFAP2/ELN,2
R-HSA-977444,R-HSA-977444,GABA B receptor activation,2/249,29/8183,0.220299423424568,0.526536083231475,0.439378351428501,GNG2/GNB2,2
R-HSA-991365,R-HSA-991365,Activation of GABAB receptors,2/249,29/8183,0.220299423424568,0.526536083231475,0.439378351428501,GNG2/GNB2,2
R-HSA-8939211,R-HSA-8939211,ESR-mediated signaling,8/249,190/8183,0.222038995082054,0.52905587717082,0.441481042853207,TFF3/HIST1H4C/GNG2/HIST1H2AC/FOS/GNB2/POLR2H/JUN,8
R-HSA-6807070,R-HSA-6807070,PTEN Regulation,6/249,134/8183,0.223521282064796,0.530949014627762,0.443060808497669,PSMB9/EGR1/PSMB8/PSMD7/PSMD6/JUN,6
R-HSA-389356,R-HSA-389356,CD28 co-stimulation,2/249,30/8183,0.231619604327523,0.545608357930177,0.455293584746753,CDC42/RAC1,2
R-HSA-380270,R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,4/249,81/8183,0.232519624040192,0.545608357930177,0.455293584746753,TUBA1A/YWHAG/DYNLL1/TUBB4B,4
R-HSA-380287,R-HSA-380287,Centrosome maturation,4/249,81/8183,0.232519624040192,0.545608357930177,0.455293584746753,TUBA1A/YWHAG/DYNLL1/TUBB4B,4
R-HSA-5628897,R-HSA-5628897,TP53 Regulates Metabolic Genes,4/249,81/8183,0.232519624040192,0.545608357930177,0.455293584746753,COX4I1/YWHAH/COX6C/YWHAG,4
R-HSA-69620,R-HSA-69620,Cell Cycle Checkpoints,11/249,280/8183,0.233331818610236,0.545855042324552,0.455499435373092,RPS27/HIST1H4C/PSMB9/PSMB8/MAD1L1/CDKN1A/YWHAH/PSMD7/PSMD6/YWHAG/DYNLL1,11
R-HSA-201681,R-HSA-201681,TCF dependent signaling in response to WNT,8/249,193/8183,0.234434817923312,0.546778487724461,0.456270022480734,SOX4/HIST1H4C/HIST1H2AC/PSMB9/PSMB8/RBX1/PSMD7/PSMD6,8
R-HSA-388396,R-HSA-388396,GPCR downstream signalling,17/249,461/8183,0.238644418182686,0.552670303079252,0.461186563245845,GRP/NPW/TAC3/RHOA/RAMP1/RGS7/OR51E1/PSAP/GNG2/RBP1/CDC42/RGS2/RHOB/GNRH2/GNB2/CAMK2B/CALCB,17
R-HSA-5668541,R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,4/249,82/8183,0.239108654441024,0.552670303079252,0.461186563245845,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-69002,R-HSA-69002,DNA Replication Pre-Initiation,4/249,82/8183,0.239108654441024,0.552670303079252,0.461186563245845,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-2122948,R-HSA-2122948,Activated NOTCH1 Transmits Signal to the Nucleus,2/249,31/8183,0.242975358742283,0.556608240204875,0.464472652038974,DLK1/NCSTN,2
R-HSA-450282,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,2/249,31/8183,0.242975358742283,0.556608240204875,0.464472652038974,FOS/JUN,2
R-HSA-5362517,R-HSA-5362517,Signaling by Retinoic Acid,2/249,31/8183,0.242975358742283,0.556608240204875,0.464472652038974,FABP5/PDHB,2
R-HSA-2029482,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,3/249,57/8183,0.250495238537228,0.57009135604546,0.475723902235917,BRK1/CDC42/RAC1,3
R-HSA-2559583,R-HSA-2559583,Cellular Senescence,7/249,168/8183,0.250852926871508,0.57009135604546,0.475723902235917,TERF2IP/HIST1H4C/HIST1H1C/HIST1H2AC/FOS/CDKN1A/JUN,7
R-HSA-174143,R-HSA-174143,APC/C-mediated degradation of cell cycle proteins,4/249,84/8183,0.252414049339642,0.57009135604546,0.475723902235917,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-453276,R-HSA-453276,Regulation of mitotic cell cycle,4/249,84/8183,0.252414049339642,0.57009135604546,0.475723902235917,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-168274,R-HSA-168274,Export of Viral Ribonucleoproteins from Nucleus,2/249,32/8183,0.254354097694316,0.57009135604546,0.475723902235917,HSPA1A/HSPA1B,2
R-HSA-1980145,R-HSA-1980145,Signaling by NOTCH2,2/249,32/8183,0.254354097694316,0.57009135604546,0.475723902235917,MDK/NCSTN,2
R-HSA-500792,R-HSA-500792,GPCR ligand binding,9/249,227/8183,0.254643184864273,0.57009135604546,0.475723902235917,GRP/NPW/TAC3/RAMP1/PSAP/GNG2/GNRH2/GNB2/CALCB,9
R-HSA-418555,R-HSA-418555,G alpha (s) signalling events,5/249,112/8183,0.254768805486637,0.57009135604546,0.475723902235917,RAMP1/OR51E1/GNG2/GNB2/CALCB,5
R-HSA-948021,R-HSA-948021,Transport to the Golgi and subsequent modification,7/249,170/8183,0.260172776765528,0.570330244018989,0.475923246986121,TUBB2B/TUBA1A/TUBB2A/TUBB3/FOLR1/DYNLL1/TUBB4B,7
R-HSA-5663202,R-HSA-5663202,Diseases of signal transduction,13/249,348/8183,0.26165215775921,0.570330244018989,0.475923246986121,RBP1/OS9/PSMB9/PSMB8/HGF/RAC1/CDKN1A/RBX1/PSMD7/PSMD6/POLR2H/CAMK2B/NCSTN,13
R-HSA-8864260,R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,2/249,33/8183,0.265743959558327,0.570330244018989,0.475923246986121,CDKN1A/CITED4,2
R-HSA-202424,R-HSA-202424,Downstream TCR signaling,4/249,86/8183,0.265870702994508,0.570330244018989,0.475923246986121,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-2565942,R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,4/249,86/8183,0.265870702994508,0.570330244018989,0.475923246986121,TUBA1A/YWHAG/DYNLL1/TUBB4B,4
R-HSA-1170546,R-HSA-1170546,Prolactin receptor signaling,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,RBX1,1
R-HSA-1234158,R-HSA-1234158,Regulation of gene expression by Hypoxia-inducible Factor,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,CA9,1
R-HSA-196025,R-HSA-196025,Formation of annular gap junctions,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,AP2M1,1
R-HSA-209776,R-HSA-209776,Amine-derived hormones,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,TPH1,1
R-HSA-3270619,R-HSA-3270619,IRF3-mediated induction of type I IFN,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,PRKDC,1
R-HSA-351906,R-HSA-351906,Apoptotic cleavage of cell adhesion  proteins,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,DSP,1
R-HSA-442729,R-HSA-442729,CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,CAMK2B,1
R-HSA-5578768,R-HSA-5578768,Physiological factors,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,NPPA,1
R-HSA-83936,R-HSA-83936,Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,SLC25A6,1
R-HSA-8875656,R-HSA-8875656,MET receptor recycling,1/249,10/8183,0.265957108609891,0.570330244018989,0.475923246986121,HGF,1
R-HSA-446652,R-HSA-446652,Interleukin-1 family signaling,5/249,115/8183,0.272215404632448,0.574051738053283,0.479028720600776,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-381676,R-HSA-381676,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,2/249,34/8183,0.277133777749553,0.574051738053283,0.479028720600776,GNG2/GNB2,2
R-HSA-5576892,R-HSA-5576892,Phase 0 - rapid depolarisation,2/249,34/8183,0.277133777749553,0.574051738053283,0.479028720600776,CACNA2D1/CAMK2B,2
R-HSA-9007101,R-HSA-9007101,Rab regulation of trafficking,5/249,116/8183,0.278088234410843,0.574051738053283,0.479028720600776,RAB13/GABARAPL2/MAP1LC3B/GABARAP/RAB7A,5
R-HSA-1257604,R-HSA-1257604,PIP3 activates AKT signaling,9/249,233/8183,0.278991947459704,0.574051738053283,0.479028720600776,PSMB9/EGR1/PSMB8/HGF/RAC1/CDKN1A/PSMD7/PSMD6/JUN,9
R-HSA-1268020,R-HSA-1268020,Mitochondrial protein import,3/249,61/8183,0.283655580646093,0.574051738053283,0.479028720600776,TOMM7/SLC25A6/CHCHD2,3
R-HSA-6796648,R-HSA-6796648,TP53 Regulates Transcription of DNA Repair Genes,3/249,61/8183,0.283655580646093,0.574051738053283,0.479028720600776,FOS/POLR2H/JUN,3
R-HSA-69239,R-HSA-69239,Synthesis of DNA,5/249,117/8183,0.283986830425183,0.574051738053283,0.479028720600776,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-1187000,R-HSA-1187000,Fertilization,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,CD9,1
R-HSA-140342,R-HSA-140342,Apoptosis induced DNA fragmentation,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,HIST1H1C,1
R-HSA-174403,R-HSA-174403,Glutathione synthesis and recycling,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,GGCT,1
R-HSA-190873,R-HSA-190873,Gap junction degradation,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,AP2M1,1
R-HSA-193692,R-HSA-193692,Regulated proteolysis of p75NTR,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,NCSTN,1
R-HSA-2022857,R-HSA-2022857,Keratan sulfate degradation,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,HEXB,1
R-HSA-2032785,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,NPPA,1
R-HSA-2160916,R-HSA-2160916,Hyaluronan uptake and degradation,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,HEXB,1
R-HSA-2453902,R-HSA-2453902,The canonical retinoid cycle in rods (twilight vision),1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,RBP1,1
R-HSA-388844,R-HSA-388844,Receptor-type tyrosine-protein phosphatases,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,SLITRK6,1
R-HSA-391160,R-HSA-391160,Signal regulatory protein family interactions,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,CD47,1
R-HSA-5686938,R-HSA-5686938,Regulation of TLR by endogenous ligand,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,S100A1,1
R-HSA-879415,R-HSA-879415,Advanced glycosylation endproduct receptor signaling,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,DDOST,1
R-HSA-8851805,R-HSA-8851805,MET activates RAS signaling,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,HGF,1
R-HSA-8934903,R-HSA-8934903,Receptor Mediated Mitophagy,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,MAP1LC3B,1
R-HSA-9013700,R-HSA-9013700,NOTCH4 Activation and Transmission of Signal to the Nucleus,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,NCSTN,1
R-HSA-9614399,R-HSA-9614399,Regulation of localization of FOXO transcription factors,1/249,11/8183,0.288320583460758,0.574051738053283,0.479028720600776,YWHAG,1
R-HSA-1566948,R-HSA-1566948,Elastic fibre formation,2/249,35/8183,0.288513049695173,0.574051738053283,0.479028720600776,MFAP2/ELN,2
R-HSA-2142753,R-HSA-2142753,Arachidonic acid metabolism,2/249,35/8183,0.288513049695173,0.574051738053283,0.479028720600776,PON3/PON2,2
R-HSA-432040,R-HSA-432040,Vasopressin regulates renal water homeostasis via Aquaporins,2/249,35/8183,0.288513049695173,0.574051738053283,0.479028720600776,GNG2/GNB2,2
R-HSA-1221632,R-HSA-1221632,Meiotic synapsis,3/249,62/8183,0.292011322301445,0.579518613924719,0.483590662287876,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-193704,R-HSA-193704,p75 NTR receptor-mediated signalling,4/249,90/8183,0.293150591457294,0.580287837448797,0.484232555929457,RHOA/RAC1/BEX3/NCSTN,4
R-HSA-8875878,R-HSA-8875878,MET promotes cell motility,2/249,36/8183,0.299871907038304,0.590878180308876,0.493069875032768,HGF/RAC1,2
R-HSA-202733,R-HSA-202733,Cell surface interactions at the vascular wall,4/249,91/8183,0.300031407617979,0.590878180308876,0.493069875032768,BSG/EPCAM/MIF/CD47,4
R-HSA-111932,R-HSA-111932,CaMK IV-mediated phosphorylation of CREB,1/249,12/8183,0.310005382129171,0.599809912290026,0.500523133789877,CAMK2B,1
R-HSA-3371511,R-HSA-3371511,HSF1 activation,1/249,12/8183,0.310005382129171,0.599809912290026,0.500523133789877,HSBP1,1
R-HSA-416993,R-HSA-416993,Trafficking of GluR2-containing AMPA receptors,1/249,12/8183,0.310005382129171,0.599809912290026,0.500523133789877,AP2M1,1
R-HSA-451306,R-HSA-451306,Ionotropic activity of kainate receptors,1/249,12/8183,0.310005382129171,0.599809912290026,0.500523133789877,GRIK2,1
R-HSA-451308,R-HSA-451308,Activation of Ca-permeable Kainate Receptor,1/249,12/8183,0.310005382129171,0.599809912290026,0.500523133789877,GRIK2,1
R-HSA-6785631,R-HSA-6785631,ERBB2 Regulates Cell Motility,1/249,12/8183,0.310005382129171,0.599809912290026,0.500523133789877,RHOA,1
R-HSA-74217,R-HSA-74217,Purine salvage,1/249,12/8183,0.310005382129171,0.599809912290026,0.500523133789877,APRT,1
R-HSA-9006925,R-HSA-9006925,Intracellular signaling by second messengers,10/249,271/8183,0.311123294199376,0.600467957804795,0.501072252763205,PSMB9/EGR1/PSMB8/HGF/RAC1/CDKN1A/PSMD7/PSMD6/CAMK2B/JUN,10
R-HSA-375276,R-HSA-375276,Peptide ligand-binding receptors,4/249,93/8183,0.313847929346021,0.6042159637285,0.504199849743444,GRP/NPW/TAC3/PSAP,4
R-HSA-3214858,R-HSA-3214858,RMTs methylate histone arginines,3/249,65/8183,0.317162792157487,0.607922682688049,0.507292994007481,HIST1H4C/HIST1H2AC/RPS2,3
R-HSA-8856825,R-HSA-8856825,Cargo recognition for clathrin-mediated endocytosis,4/249,94/8183,0.320778599688295,0.607922682688049,0.507292994007481,VAMP8/SYT11/AP2M1/SYT1,4
R-HSA-9609507,R-HSA-9609507,Protein localization,6/249,153/8183,0.322285986597328,0.607922682688049,0.507292994007481,SEC61G/CYB5A/TOMM7/SLC25A6/SERP1/CHCHD2,6
R-HSA-1660662,R-HSA-1660662,Glycosphingolipid metabolism,2/249,38/8183,0.322491905056581,0.607922682688049,0.507292994007481,PSAP/HEXB,2
R-HSA-418597,R-HSA-418597,G alpha (z) signalling events,2/249,38/8183,0.322491905056581,0.607922682688049,0.507292994007481,GNG2/GNB2,2
R-HSA-445717,R-HSA-445717,Aquaporin-mediated transport,2/249,38/8183,0.322491905056581,0.607922682688049,0.507292994007481,GNG2/GNB2,2
R-HSA-977443,R-HSA-977443,GABA receptor activation,2/249,38/8183,0.322491905056581,0.607922682688049,0.507292994007481,GNG2/GNB2,2
R-HSA-73856,R-HSA-73856,RNA Polymerase II Transcription Termination,3/249,66/8183,0.325560319581448,0.607922682688049,0.507292994007481,SNRPF/THOC7/SNRPE,3
R-HSA-69306,R-HSA-69306,DNA Replication,5/249,124/8183,0.325855491211162,0.607922682688049,0.507292994007481,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-5607764,R-HSA-5607764,CLEC7A (Dectin-1) signaling,4/249,95/8183,0.327720916886785,0.607922682688049,0.507292994007481,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-112308,R-HSA-112308,Presynaptic depolarization and calcium channel opening,1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,CACNA2D1,1
R-HSA-1834941,R-HSA-1834941,STING mediated induction of host immune responses,1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,PRKDC,1
R-HSA-2024101,R-HSA-2024101,CS/DS degradation,1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,HEXB,1
R-HSA-2559584,R-HSA-2559584,Formation of Senescence-Associated Heterochromatin Foci (SAHF),1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,HIST1H1C,1
R-HSA-399955,R-HSA-399955,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,RAC1,1
R-HSA-428540,R-HSA-428540,Activation of RAC1,1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,RAC1,1
R-HSA-5099900,R-HSA-5099900,WNT5A-dependent internalization of FZD4,1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,AP2M1,1
R-HSA-5140745,R-HSA-5140745,WNT5A-dependent internalization of FZD2, FZD5 and ROR2,1/249,13/8183,0.331032020221184,0.607922682688049,0.507292994007481,AP2M1,1
R-HSA-5675221,R-HSA-5675221,Negative regulation of MAPK pathway,2/249,39/8183,0.333736228285136,0.607922682688049,0.507292994007481,DUSP1/DUSP2,2
R-HSA-73933,R-HSA-73933,Resolution of Abasic Sites (AP sites),2/249,39/8183,0.333736228285136,0.607922682688049,0.507292994007481,BPHL/NTHL1,2
R-HSA-9009391,R-HSA-9009391,Non-genomic estrogen signaling,3/249,67/8183,0.333957814675393,0.607922682688049,0.507292994007481,GNG2/FOS/GNB2,3
R-HSA-5617472,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,4/249,96/8183,0.33467246132438,0.607922682688049,0.507292994007481,HIST1H4C/HIST1H2AC/POLR2H/JUN,4
R-HSA-5619507,R-HSA-5619507,Activation of HOX genes during differentiation,4/249,96/8183,0.33467246132438,0.607922682688049,0.507292994007481,HIST1H4C/HIST1H2AC/POLR2H/JUN,4
R-HSA-5620912,R-HSA-5620912,Anchoring of the basal body to the plasma membrane,4/249,96/8183,0.33467246132438,0.607922682688049,0.507292994007481,TUBA1A/YWHAG/DYNLL1/TUBB4B,4
R-HSA-157579,R-HSA-157579,Telomere Maintenance,3/249,68/8183,0.342351330215611,0.618958376876936,0.516501945253183,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-448424,R-HSA-448424,Interleukin-17 signaling,3/249,68/8183,0.342351330215611,0.618958376876936,0.516501945253183,FOS/IL17RB/JUN,3
R-HSA-177504,R-HSA-177504,Retrograde neurotrophin signalling,1/249,14/8183,0.351420395614688,0.629458342029093,0.525263846907288,AP2M1,1
R-HSA-198323,R-HSA-198323,AKT phosphorylates targets in the cytosol,1/249,14/8183,0.351420395614688,0.629458342029093,0.525263846907288,CDKN1A,1
R-HSA-2142845,R-HSA-2142845,Hyaluronan metabolism,1/249,14/8183,0.351420395614688,0.629458342029093,0.525263846907288,HEXB,1
R-HSA-6804116,R-HSA-6804116,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,1/249,14/8183,0.351420395614688,0.629458342029093,0.525263846907288,CDKN1A,1
R-HSA-69242,R-HSA-69242,S Phase,6/249,159/8183,0.354876658226895,0.634177731831395,0.529202034198001,PSMB9/PSMB8/CDKN1A/RBX1/PSMD7/PSMD6,6
R-HSA-373752,R-HSA-373752,Netrin-1 signaling,2/249,41/8183,0.35605546703874,0.63481482806907,0.529733671636584,CDC42/RAC1,2
R-HSA-5617833,R-HSA-5617833,Cilium Assembly,7/249,190/8183,0.35760589097808,0.636110018053174,0.530814468296349,TUBB2B/TUBA1A/TUBB2A/TUBB3/YWHAG/DYNLL1/TUBB4B,7
R-HSA-204998,R-HSA-204998,Cell death signalling via NRAGE, NRIF and NADE,3/249,70/8183,0.359111245270384,0.63731926746836,0.531823550164489,RAC1/BEX3/NCSTN,3
R-HSA-69206,R-HSA-69206,G1/S Transition,5/249,130/8183,0.362247798547796,0.641411239630502,0.535238176511954,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-3899300,R-HSA-3899300,SUMOylation of transcription cofactors,2/249,42/8183,0.367116653046813,0.646858986440549,0.539784155578969,PARK7/DDX17,2
R-HSA-170834,R-HSA-170834,Signaling by TGF-beta Receptor Complex,3/249,71/8183,0.367470360934772,0.646858986440549,0.539784155578969,RHOA/PPP1R15A/JUNB,3
R-HSA-983705,R-HSA-983705,Signaling by the B Cell Receptor (BCR),4/249,101/8183,0.369486861336649,0.646858986440549,0.539784155578969,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-204174,R-HSA-204174,Regulation of pyruvate dehydrogenase (PDH) complex,1/249,15/8183,0.371189806985963,0.646858986440549,0.539784155578969,PDHB,1
R-HSA-264642,R-HSA-264642,Acetylcholine Neurotransmitter Release Cycle,1/249,15/8183,0.371189806985963,0.646858986440549,0.539784155578969,SYT1,1
R-HSA-5635838,R-HSA-5635838,Activation of SMO,1/249,15/8183,0.371189806985963,0.646858986440549,0.539784155578969,EVC2,1
R-HSA-888590,R-HSA-888590,GABA synthesis, release, reuptake and degradation,1/249,15/8183,0.371189806985963,0.646858986440549,0.539784155578969,SYT1,1
R-HSA-5250924,R-HSA-5250924,B-WICH complex positively regulates rRNA expression,3/249,72/8183,0.375810928265584,0.651968621620294,0.54404799077123,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-73772,R-HSA-73772,RNA Polymerase I Promoter Escape,3/249,72/8183,0.375810928265584,0.651968621620294,0.54404799077123,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-1980143,R-HSA-1980143,Signaling by NOTCH1,3/249,73/8183,0.384129607428084,0.66232335432157,0.55268870036106,DLK1/RBX1/NCSTN,3
R-HSA-73728,R-HSA-73728,RNA Polymerase I Promoter Opening,2/249,44/8183,0.389011292787334,0.66232335432157,0.55268870036106,HIST1H4C/HIST1H2AC,2
R-HSA-202403,R-HSA-202403,TCR signaling,4/249,104/8183,0.390340758810815,0.66232335432157,0.55268870036106,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-2559580,R-HSA-2559580,Oxidative Stress Induced Senescence,4/249,104/8183,0.390340758810815,0.66232335432157,0.55268870036106,HIST1H4C/HIST1H2AC/FOS/JUN,4
R-HSA-181430,R-HSA-181430,Norepinephrine Neurotransmitter Release Cycle,1/249,16/8183,0.390358971782791,0.66232335432157,0.55268870036106,SYT1,1
R-HSA-205043,R-HSA-205043,NRIF signals cell death from the nucleus,1/249,16/8183,0.390358971782791,0.66232335432157,0.55268870036106,NCSTN,1
R-HSA-2173791,R-HSA-2173791,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),1/249,16/8183,0.390358971782791,0.66232335432157,0.55268870036106,RHOA,1
R-HSA-399954,R-HSA-399954,Sema3A PAK dependent Axon repulsion,1/249,16/8183,0.390358971782791,0.66232335432157,0.55268870036106,RAC1,1
R-HSA-399956,R-HSA-399956,CRMPs in Sema3A signaling,1/249,16/8183,0.390358971782791,0.66232335432157,0.55268870036106,DPYSL3,1
R-HSA-9617828,R-HSA-9617828,FOXO-mediated transcription of cell cycle genes,1/249,16/8183,0.390358971782791,0.66232335432157,0.55268870036106,CDKN1A,1
R-HSA-1912408,R-HSA-1912408,Pre-NOTCH Transcription and Translation,3/249,74/8183,0.392423177849186,0.662911801530791,0.553179741664636,HIST1H4C/HIST1H2AC/JUN,3
R-HSA-6806834,R-HSA-6806834,Signaling by MET,3/249,74/8183,0.392423177849186,0.662911801530791,0.553179741664636,SPINT2/HGF/RAC1,3
R-HSA-1474165,R-HSA-1474165,Reproduction,4/249,105/8183,0.397273607824713,0.669640229783141,0.558794410454435,CD9/TERF2IP/HIST1H4C/HIST1H2AC,4
R-HSA-5334118,R-HSA-5334118,DNA methylation,2/249,45/8183,0.399833693463258,0.672487170705087,0.561170096088783,HIST1H4C/HIST1H2AC,2
R-HSA-8878171,R-HSA-8878171,Transcriptional regulation by RUNX1,7/249,200/8183,0.407780384538076,0.683347068627673,0.570232350695577,HIST1H4C/HIST1H2AC/PSMB9/PSMB8/PSMD7/PSMD6/CTSL,7
R-HSA-163560,R-HSA-163560,Triglyceride catabolism,1/249,17/8183,0.408946043660602,0.683347068627673,0.570232350695577,FABP5,1
R-HSA-5576893,R-HSA-5576893,Phase 2 - plateau phase,1/249,17/8183,0.408946043660602,0.683347068627673,0.570232350695577,CACNA2D1,1
R-HSA-9012852,R-HSA-9012852,Signaling by NOTCH3,2/249,46/8183,0.41056611702058,0.684572445658504,0.571254890568591,YBX1/NCSTN,2
R-HSA-381038,R-HSA-381038,XBP1(S) activates chaperone genes,2/249,47/8183,0.421204014705761,0.697788625220702,0.582283390557772,PDIA6/SERP1,2
R-HSA-421270,R-HSA-421270,Cell-cell junction organization,2/249,47/8183,0.421204014705761,0.697788625220702,0.582283390557772,CLDN18/CDH18,2
R-HSA-5625886,R-HSA-5625886,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,2/249,47/8183,0.421204014705761,0.697788625220702,0.582283390557772,HIST1H4C/HIST1H2AC,2
R-HSA-70326,R-HSA-70326,Glucose metabolism,3/249,78/8183,0.425286069038019,0.701318684882904,0.585229118009732,PGAM2/MDH2/ALDOA,3
R-HSA-181429,R-HSA-181429,Serotonin Neurotransmitter Release Cycle,1/249,18/8183,0.426968629397623,0.701318684882904,0.585229118009732,SYT1,1
R-HSA-438066,R-HSA-438066,Unblocking of NMDA receptors, glutamate binding and activation,1/249,18/8183,0.426968629397623,0.701318684882904,0.585229118009732,CAMK2B,1
R-HSA-73780,R-HSA-73780,RNA Polymerase III Chain Elongation,1/249,18/8183,0.426968629397623,0.701318684882904,0.585229118009732,POLR2H,1
R-HSA-75153,R-HSA-75153,Apoptotic execution phase,2/249,48/8183,0.431743195420042,0.707655513512257,0.590517008821245,HIST1H1C/DSP,2
R-HSA-2029480,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,3/249,79/8183,0.433409876504772,0.708882255639161,0.591540687825425,BRK1/CDC42/RAC1,3
R-HSA-5619115,R-HSA-5619115,Disorders of transmembrane transporters,5/249,142/8183,0.435046512714596,0.710054773394647,0.59251911824042,OS9/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-111885,R-HSA-111885,Opioid Signalling,3/249,80/8183,0.441491685466877,0.713327687515813,0.595250265557237,GNG2/GNB2/CAMK2B,3
R-HSA-427359,R-HSA-427359,SIRT1 negatively regulates rRNA expression,2/249,49/8183,0.442179808318771,0.713327687515813,0.595250265557237,HIST1H4C/HIST1H2AC,2
R-HSA-8848021,R-HSA-8848021,Signaling by PTK6,2/249,49/8183,0.442179808318771,0.713327687515813,0.595250265557237,RHOA/RAC1,2
R-HSA-9006927,R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,2/249,49/8183,0.442179808318771,0.713327687515813,0.595250265557237,RHOA/RAC1,2
R-HSA-1592389,R-HSA-1592389,Activation of Matrix Metalloproteinases,1/249,19/8183,0.444443805304541,0.713327687515813,0.595250265557237,TIMP1,1
R-HSA-3928664,R-HSA-3928664,Ephrin signaling,1/249,19/8183,0.444443805304541,0.713327687515813,0.595250265557237,RAC1,1
R-HSA-442982,R-HSA-442982,Ras activation upon Ca2+ influx through NMDA receptor,1/249,19/8183,0.444443805304541,0.713327687515813,0.595250265557237,CAMK2B,1
R-HSA-8851708,R-HSA-8851708,Signaling by FGFR2 IIIa TM,1/249,19/8183,0.444443805304541,0.713327687515813,0.595250265557237,POLR2H,1
R-HSA-2219528,R-HSA-2219528,PI3K/AKT Signaling in Cancer,3/249,81/8183,0.449529072444827,0.71999262225603,0.600811950941765,HGF/RAC1/CDKN1A,3
R-HSA-373076,R-HSA-373076,Class A/1 (Rhodopsin-like receptors),5/249,145/8183,0.453030747231084,0.724098834083638,0.604238459857085,GRP/NPW/TAC3/PSAP/GNRH2,5
R-HSA-983712,R-HSA-983712,Ion channel transport,5/249,146/8183,0.458992982209297,0.729900899153612,0.609080106738493,ATP6AP1/SGK1/ANO10/CAMK2B/ATP6V0E2,5
R-HSA-210500,R-HSA-210500,Glutamate Neurotransmitter Release Cycle,1/249,20/8183,0.461388133143734,0.729900899153612,0.609080106738493,SYT1,1
R-HSA-420029,R-HSA-420029,Tight junction interactions,1/249,20/8183,0.461388133143734,0.729900899153612,0.609080106738493,CLDN18,1
R-HSA-445144,R-HSA-445144,Signal transduction by L1,1/249,20/8183,0.461388133143734,0.729900899153612,0.609080106738493,RAC1,1
R-HSA-6803157,R-HSA-6803157,Antimicrobial peptides,1/249,20/8183,0.461388133143734,0.729900899153612,0.609080106738493,CHGA,1
R-HSA-1852241,R-HSA-1852241,Organelle biogenesis and maintenance,9/249,277/8183,0.46895576209576,0.736656678782172,0.614717599420084,TUBB2B/TUBA1A/TUBB2A/ATP5F1E/TUBB3/ATP5ME/YWHAG/DYNLL1/TUBB4B,9
R-HSA-453279,R-HSA-453279,Mitotic G1-G1/S phases,5/249,148/8183,0.470861870205718,0.736656678782172,0.614717599420084,PSMB9/PSMB8/CDKN1A/PSMD7/PSMD6,5
R-HSA-191859,R-HSA-191859,snRNP Assembly,2/249,52/8183,0.472840490037073,0.736656678782172,0.614717599420084,SNRPF/SNRPE,2
R-HSA-194441,R-HSA-194441,Metabolism of non-coding RNA,2/249,52/8183,0.472840490037073,0.736656678782172,0.614717599420084,SNRPF/SNRPE,2
R-HSA-210991,R-HSA-210991,Basigin interactions,1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,BSG,1
R-HSA-5223345,R-HSA-5223345,Miscellaneous transport and binding events,1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,AZGP1,1
R-HSA-6783783,R-HSA-6783783,Interleukin-10 signaling,1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,TIMP1,1
R-HSA-6807004,R-HSA-6807004,Negative regulation of MET activity,1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,HGF,1
R-HSA-8956321,R-HSA-8956321,Nucleotide salvage,1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,APRT,1
R-HSA-901032,R-HSA-901032,ER Quality Control Compartment (ERQC),1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,OS9,1
R-HSA-9617324,R-HSA-9617324,Negative regulation of NMDA receptor-mediated neuronal transmission,1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,CAMK2B,1
R-HSA-9634638,R-HSA-9634638,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,1/249,21/8183,0.477817675572647,0.736656678782172,0.614717599420084,FOS,1
R-HSA-72163,R-HSA-72163,mRNA Splicing - Major Pathway,6/249,182/8183,0.480001926248745,0.736656678782172,0.614717599420084,SNRPF/YBX1/SNRPE/LSM3/POLR2H/LSM5,6
R-HSA-69473,R-HSA-69473,G2/M DNA damage checkpoint,3/249,85/8183,0.481189645515441,0.736656678782172,0.614717599420084,HIST1H4C/YWHAH/YWHAG,3
R-HSA-4086398,R-HSA-4086398,Ca2+ pathway,2/249,53/8183,0.482834558890905,0.736656678782172,0.614717599420084,GNG2/GNB2,2
R-HSA-6781823,R-HSA-6781823,Formation of TC-NER Pre-Incision Complex,2/249,53/8183,0.482834558890905,0.736656678782172,0.614717599420084,RBX1/POLR2H,2
R-HSA-6809371,R-HSA-6809371,Formation of the cornified envelope,2/249,53/8183,0.482834558890905,0.736656678782172,0.614717599420084,KRT12/DSP,2
R-HSA-8866654,R-HSA-8866654,E3 ubiquitin ligases ubiquitinate target proteins,2/249,53/8183,0.482834558890905,0.736656678782172,0.614717599420084,HLA-A/PRKDC,2
R-HSA-5578749,R-HSA-5578749,Transcriptional regulation by small RNAs,3/249,86/8183,0.488972257895716,0.741582615931689,0.618828144191701,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-212300,R-HSA-212300,PRC2 methylates histones and DNA,2/249,54/8183,0.492711349441247,0.741582615931689,0.618828144191701,HIST1H4C/HIST1H2AC,2
R-HSA-2299718,R-HSA-2299718,Condensation of Prophase Chromosomes,2/249,54/8183,0.492711349441247,0.741582615931689,0.618828144191701,HIST1H4C/HIST1H2AC,2
R-HSA-388841,R-HSA-388841,Costimulation by the CD28 family,2/249,54/8183,0.492711349441247,0.741582615931689,0.618828144191701,CDC42/RAC1,2
R-HSA-1251985,R-HSA-1251985,Nuclear signaling by ERBB4,1/249,22/8183,0.493748011125502,0.741582615931689,0.618828144191701,NCSTN,1
R-HSA-71403,R-HSA-71403,Citric acid cycle (TCA cycle),1/249,22/8183,0.493748011125502,0.741582615931689,0.618828144191701,MDH2,1
R-HSA-9006115,R-HSA-9006115,Signaling by NTRK2 (TRKB),1/249,22/8183,0.493748011125502,0.741582615931689,0.618828144191701,RAC1,1
R-HSA-9620244,R-HSA-9620244,Long-term potentiation,1/249,22/8183,0.493748011125502,0.741582615931689,0.618828144191701,CAMK2B,1
R-HSA-427413,R-HSA-427413,NoRC negatively regulates rRNA expression,3/249,87/8183,0.496698092453177,0.743121952274908,0.620112673564554,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-5250913,R-HSA-5250913,Positive epigenetic regulation of rRNA expression,3/249,87/8183,0.496698092453177,0.743121952274908,0.620112673564554,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-2219530,R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,2/249,55/8183,0.502468725452037,0.750301462377122,0.626103756442322,HGF/RAC1,2
R-HSA-6811442,R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,6/249,187/8183,0.5064656604646,0.753061226116381,0.628406695368456,TUBB2B/TUBA1A/TUBB2A/TUBB3/DYNLL1/TUBB4B,6
R-HSA-167242,R-HSA-167242,Abortive elongation of HIV-1 transcript in the absence of Tat,1/249,23/8183,0.509194248747087,0.753061226116381,0.628406695368456,POLR2H,1
R-HSA-212676,R-HSA-212676,Dopamine Neurotransmitter Release Cycle,1/249,23/8183,0.509194248747087,0.753061226116381,0.628406695368456,SYT1,1
R-HSA-381753,R-HSA-381753,Olfactory Signaling Pathway,1/249,23/8183,0.509194248747087,0.753061226116381,0.628406695368456,OR51E1,1
R-HSA-73980,R-HSA-73980,RNA Polymerase III Transcription Termination,1/249,23/8183,0.509194248747087,0.753061226116381,0.628406695368456,POLR2H,1
R-HSA-432722,R-HSA-432722,Golgi Associated Vesicle Biogenesis,2/249,56/8183,0.512104787848957,0.75356067745361,0.628823472322892,VAMP8/FTH1,2
R-HSA-9614085,R-HSA-9614085,FOXO-mediated transcription,2/249,56/8183,0.512104787848957,0.75356067745361,0.628823472322892,CDKN1A/YWHAG,2
R-HSA-194840,R-HSA-194840,Rho GTPase cycle,4/249,123/8183,0.518246978726233,0.75356067745361,0.628823472322892,RHOA/CDC42/RAC1/RHOB,4
R-HSA-166520,R-HSA-166520,Signaling by NTRKs,3/249,90/8183,0.51951825482485,0.75356067745361,0.628823472322892,RHOA/RAC1/AP2M1,3
R-HSA-1912422,R-HSA-1912422,Pre-NOTCH Expression and Processing,3/249,90/8183,0.51951825482485,0.75356067745361,0.628823472322892,HIST1H4C/HIST1H2AC/JUN,3
R-HSA-5250941,R-HSA-5250941,Negative epigenetic regulation of rRNA expression,3/249,90/8183,0.51951825482485,0.75356067745361,0.628823472322892,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-427389,R-HSA-427389,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,2/249,57/8183,0.521617862369383,0.75356067745361,0.628823472322892,HIST1H4C/HIST1H2AC,2
R-HSA-8873719,R-HSA-8873719,RAB geranylgeranylation,2/249,57/8183,0.521617862369383,0.75356067745361,0.628823472322892,RAB13/RAB7A,2
R-HSA-8986944,R-HSA-8986944,Transcriptional Regulation by MECP2,2/249,57/8183,0.521617862369383,0.75356067745361,0.628823472322892,SGK1/CAMK2B,2
R-HSA-72172,R-HSA-72172,mRNA Splicing,6/249,190/8183,0.522113250761375,0.75356067745361,0.628823472322892,SNRPF/YBX1/SNRPE/LSM3/POLR2H/LSM5,6
R-HSA-1266695,R-HSA-1266695,Interleukin-7 signaling,1/249,24/8183,0.524171041891937,0.75356067745361,0.628823472322892,HGF,1
R-HSA-1839126,R-HSA-1839126,FGFR2 mutant receptor activation,1/249,24/8183,0.524171041891937,0.75356067745361,0.628823472322892,POLR2H,1
R-HSA-203927,R-HSA-203927,MicroRNA (miRNA) biogenesis,1/249,24/8183,0.524171041891937,0.75356067745361,0.628823472322892,POLR2H,1
R-HSA-5621481,R-HSA-5621481,C-type lectin receptors (CLRs),4/249,124/8183,0.524660028310069,0.75356067745361,0.628823472322892,PSMB9/PSMB8/PSMD7/PSMD6,4
R-HSA-73854,R-HSA-73854,RNA Polymerase I Promoter Clearance,3/249,91/8183,0.527000760979629,0.75356067745361,0.628823472322892,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-1834949,R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA ,2/249,58/8183,0.531006487739331,0.75356067745361,0.628823472322892,POLR2H/PRKDC,2
R-HSA-2644602,R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,2/249,58/8183,0.531006487739331,0.75356067745361,0.628823472322892,RBX1/NCSTN,2
R-HSA-2644603,R-HSA-2644603,Signaling by NOTCH1 in Cancer,2/249,58/8183,0.531006487739331,0.75356067745361,0.628823472322892,RBX1/NCSTN,2
R-HSA-2644606,R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,2/249,58/8183,0.531006487739331,0.75356067745361,0.628823472322892,RBX1/NCSTN,2
R-HSA-2894858,R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,2/249,58/8183,0.531006487739331,0.75356067745361,0.628823472322892,RBX1/NCSTN,2
R-HSA-2894862,R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,2/249,58/8183,0.531006487739331,0.75356067745361,0.628823472322892,RBX1/NCSTN,2
R-HSA-8943724,R-HSA-8943724,Regulation of PTEN gene transcription,2/249,58/8183,0.531006487739331,0.75356067745361,0.628823472322892,EGR1/JUN,2
R-HSA-73864,R-HSA-73864,RNA Polymerase I Transcription,3/249,92/8183,0.534418830482907,0.75562515958389,0.630546219887293,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-9006936,R-HSA-9006936,Signaling by TGF-beta family members,3/249,92/8183,0.534418830482907,0.75562515958389,0.630546219887293,RHOA/PPP1R15A/JUNB,3
R-HSA-2173788,R-HSA-2173788,Downregulation of TGF-beta receptor signaling,1/249,25/8183,0.53869260220189,0.756128525272471,0.630966263248912,PPP1R15A,1
R-HSA-418990,R-HSA-418990,Adherens junctions interactions,1/249,25/8183,0.53869260220189,0.756128525272471,0.630966263248912,CDH18,1
R-HSA-525793,R-HSA-525793,Myogenesis,1/249,25/8183,0.53869260220189,0.756128525272471,0.630966263248912,CDC42,1
R-HSA-5674400,R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,1/249,25/8183,0.53869260220189,0.756128525272471,0.630966263248912,CDKN1A,1
R-HSA-5693571,R-HSA-5693571,Nonhomologous End-Joining (NHEJ),2/249,59/8183,0.540269404356957,0.756965481240601,0.63166467755556,HIST1H4C/PRKDC,2
R-HSA-1500620,R-HSA-1500620,Meiosis,3/249,94/8183,0.549056663991472,0.761654000506242,0.635577104322089,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-6790901,R-HSA-6790901,rRNA modification in the nucleus and cytosol,2/249,60/8183,0.549405543462939,0.761654000506242,0.635577104322089,RPS2/RPS14,2
R-HSA-110373,R-HSA-110373,Resolution of AP sites via the multiple-nucleotide patch replacement pathway,1/249,26/8183,0.552772712774546,0.761654000506242,0.635577104322089,BPHL,1
R-HSA-1483191,R-HSA-1483191,Synthesis of PC,1/249,26/8183,0.552772712774546,0.761654000506242,0.635577104322089,MFSD2A,1
R-HSA-5601884,R-HSA-5601884,PIWI-interacting RNA (piRNA) biogenesis,1/249,26/8183,0.552772712774546,0.761654000506242,0.635577104322089,POLR2H,1
R-HSA-6803529,R-HSA-6803529,FGFR2 alternative splicing,1/249,26/8183,0.552772712774546,0.761654000506242,0.635577104322089,POLR2H,1
R-HSA-8874081,R-HSA-8874081,MET activates PTK2 signaling,1/249,26/8183,0.552772712774546,0.761654000506242,0.635577104322089,HGF,1
R-HSA-141424,R-HSA-141424,Amplification of signal from the kinetochores,3/249,95/8183,0.556274134005755,0.761654000506242,0.635577104322089,RPS27/MAD1L1/DYNLL1,3
R-HSA-141444,R-HSA-141444,Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,3/249,95/8183,0.556274134005755,0.761654000506242,0.635577104322089,RPS27/MAD1L1/DYNLL1,3
R-HSA-606279,R-HSA-606279,Deposition of new CENPA-containing nucleosomes at the centromere,2/249,61/8183,0.558414016778764,0.761654000506242,0.635577104322089,HIST1H4C/HIST1H2AC,2
R-HSA-774815,R-HSA-774815,Nucleosome assembly,2/249,61/8183,0.558414016778764,0.761654000506242,0.635577104322089,HIST1H4C/HIST1H2AC,2
R-HSA-9006934,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,12/249,400/8183,0.563207175492105,0.761654000506242,0.635577104322089,SPINT2/RHOA/BRK1/ATP6AP1/CDC42/HGF/RAC1/POLR2H/AP2M1/ATP6V0E2/NCSTN/CYBA,12
R-HSA-73886,R-HSA-73886,Chromosome Maintenance,3/249,96/8183,0.563422575059993,0.761654000506242,0.635577104322089,TERF2IP/HIST1H4C/HIST1H2AC,3
R-HSA-156590,R-HSA-156590,Glutathione conjugation,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,GGCT,1
R-HSA-167160,R-HSA-167160,RNA Pol II CTD phosphorylation and interaction with CE during HIV infection,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,POLR2H,1
R-HSA-389661,R-HSA-389661,Glyoxylate metabolism and glycine degradation,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,PDHB,1
R-HSA-442742,R-HSA-442742,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,CAMK2B,1
R-HSA-5218920,R-HSA-5218920,VEGFR2 mediated vascular permeability,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,RAC1,1
R-HSA-76066,R-HSA-76066,RNA Polymerase III Transcription Initiation From Type 2 Promoter,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,POLR2H,1
R-HSA-77075,R-HSA-77075,RNA Pol II CTD phosphorylation and interaction with CE,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,POLR2H,1
R-HSA-8979227,R-HSA-8979227,Triglyceride metabolism,1/249,27/8183,0.56642474103483,0.761654000506242,0.635577104322089,FABP5,1
R-HSA-216083,R-HSA-216083,Integrin cell surface interactions,2/249,62/8183,0.567294106594675,0.761654000506242,0.635577104322089,BSG/CD47,2
R-HSA-70171,R-HSA-70171,Glycolysis,2/249,62/8183,0.567294106594675,0.761654000506242,0.635577104322089,PGAM2/ALDOA,2
R-HSA-74752,R-HSA-74752,Signaling by Insulin receptor,2/249,62/8183,0.567294106594675,0.761654000506242,0.635577104322089,ATP6AP1/ATP6V0E2,2
R-HSA-73887,R-HSA-73887,Death Receptor Signalling,4/249,131/8183,0.568354988610359,0.761753561123606,0.635660184630007,RHOA/RAC1/BEX3/NCSTN,4
R-HSA-450294,R-HSA-450294,MAP kinase activation,2/249,63/8183,0.576045256289656,0.770221677698767,0.642726570427659,FOS/JUN,2
R-HSA-182971,R-HSA-182971,EGFR downregulation,1/249,28/8183,0.579661651221481,0.770221677698767,0.642726570427659,CDC42,1
R-HSA-3299685,R-HSA-3299685,Detoxification of Reactive Oxygen Species,1/249,28/8183,0.579661651221481,0.770221677698767,0.642726570427659,CYBA,1
R-HSA-76061,R-HSA-76061,RNA Polymerase III Transcription Initiation From Type 1 Promoter,1/249,28/8183,0.579661651221481,0.770221677698767,0.642726570427659,POLR2H,1
R-HSA-76071,R-HSA-76071,RNA Polymerase III Transcription Initiation From Type 3 Promoter,1/249,28/8183,0.579661651221481,0.770221677698767,0.642726570427659,POLR2H,1
R-HSA-6782210,R-HSA-6782210,Gap-filling DNA repair synthesis and ligation in TC-NER,2/249,64/8183,0.584667061266538,0.775537751370735,0.647162672264644,RBX1/POLR2H,2
R-HSA-8856828,R-HSA-8856828,Clathrin-mediated endocytosis,4/249,134/8183,0.586392511966328,0.776492314301895,0.647959226005945,VAMP8/SYT11/AP2M1/SYT1,4
R-HSA-72086,R-HSA-72086,mRNA Capping,1/249,29/8183,0.592496016499942,0.780100424089768,0.65097008391456,POLR2H,1
R-HSA-422356,R-HSA-422356,Regulation of insulin secretion,2/249,65/8183,0.593159260285873,0.780100424089768,0.65097008391456,GNG2/GNB2,2
R-HSA-6782135,R-HSA-6782135,Dual incision in TC-NER,2/249,65/8183,0.593159260285873,0.780100424089768,0.65097008391456,RBX1/POLR2H,2
R-HSA-912446,R-HSA-912446,Meiotic recombination,2/249,65/8183,0.593159260285873,0.780100424089768,0.65097008391456,HIST1H4C/HIST1H2AC,2
R-HSA-72203,R-HSA-72203,Processing of Capped Intron-Containing Pre-mRNA,7/249,239/8183,0.595538825575691,0.781897913851078,0.652470034465312,SNRPF/THOC7/YBX1/SNRPE/LSM3/POLR2H/LSM5,7
R-HSA-1500931,R-HSA-1500931,Cell-Cell communication,3/249,102/8183,0.604815293377068,0.783580039782332,0.653873717407673,CLDN18/CDH18/CD47,3
R-HSA-110314,R-HSA-110314,Recognition of DNA damage by PCNA-containing replication complex,1/249,30/8183,0.604940030712785,0.783580039782332,0.653873717407673,RBX1,1
R-HSA-1638074,R-HSA-1638074,Keratan sulfate/keratin metabolism,1/249,30/8183,0.604940030712785,0.783580039782332,0.653873717407673,HEXB,1
R-HSA-167238,R-HSA-167238,Pausing and recovery of Tat-mediated HIV elongation,1/249,30/8183,0.604940030712785,0.783580039782332,0.653873717407673,POLR2H,1
R-HSA-167243,R-HSA-167243,Tat-mediated HIV elongation arrest and recovery,1/249,30/8183,0.604940030712785,0.783580039782332,0.653873717407673,POLR2H,1
R-HSA-381042,R-HSA-381042,PERK regulates gene expression,1/249,30/8183,0.604940030712785,0.783580039782332,0.653873717407673,HSPA5,1
R-HSA-5694530,R-HSA-5694530,Cargo concentration in the ER,1/249,30/8183,0.604940030712785,0.783580039782332,0.653873717407673,FOLR1,1
R-HSA-975634,R-HSA-975634,Retinoid metabolism and transport,1/249,30/8183,0.604940030712785,0.783580039782332,0.653873717407673,RBP1,1
R-HSA-1474290,R-HSA-1474290,Collagen formation,2/249,67/8183,0.609754462952347,0.787174657858214,0.656873316892865,PPIB/CTSL,2
R-HSA-418346,R-HSA-418346,Platelet homeostasis,2/249,67/8183,0.609754462952347,0.787174657858214,0.656873316892865,GNG2/GNB2,2
R-HSA-2173789,R-HSA-2173789,TGF-beta receptor signaling activates SMADs,1/249,31/8183,0.617005519778468,0.79255950294339,0.661366806383085,PPP1R15A,1
R-HSA-2173796,R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,1/249,31/8183,0.617005519778468,0.79255950294339,0.661366806383085,JUNB,1
R-HSA-73863,R-HSA-73863,RNA Polymerase I Transcription Termination,1/249,31/8183,0.617005519778468,0.79255950294339,0.661366806383085,POLR2H,1
R-HSA-5576891,R-HSA-5576891,Cardiac conduction,3/249,105/8183,0.624518373655111,0.796977752909967,0.665053701637442,CACNA2D1/CAMK2B/NPPA,3
R-HSA-201722,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,2/249,69/8183,0.625831335854067,0.796977752909967,0.665053701637442,HIST1H4C/HIST1H2AC,2
R-HSA-6794362,R-HSA-6794362,Protein-protein interactions at synapses,2/249,69/8183,0.625831335854067,0.796977752909967,0.665053701637442,SLITRK6/SYT1,2
R-HSA-163841,R-HSA-163841,Gamma carboxylation, hypusine formation and arylsulfatase activation,1/249,32/8183,0.628703952748925,0.796977752909967,0.665053701637442,EEF2,1
R-HSA-167287,R-HSA-167287,HIV elongation arrest and recovery,1/249,32/8183,0.628703952748925,0.796977752909967,0.665053701637442,POLR2H,1
R-HSA-167290,R-HSA-167290,Pausing and recovery of HIV elongation,1/249,32/8183,0.628703952748925,0.796977752909967,0.665053701637442,POLR2H,1
R-HSA-5673000,R-HSA-5673000,RAF activation,1/249,32/8183,0.628703952748925,0.796977752909967,0.665053701637442,CAMK2B,1
R-HSA-5689901,R-HSA-5689901,Metalloprotease DUBs,1/249,32/8183,0.628703952748925,0.796977752909967,0.665053701637442,HIST1H2AC,1
R-HSA-1169408,R-HSA-1169408,ISG15 antiviral mechanism,2/249,70/8183,0.633676044400646,0.800836079996585,0.668273358273671,EIF4A2/EIF4A1,2
R-HSA-418594,R-HSA-418594,G alpha (i) signalling events,7/249,248/8183,0.634609160631854,0.800836079996585,0.668273358273671,NPW/RGS7/PSAP/GNG2/RBP1/GNB2/CAMK2B,7
R-HSA-111933,R-HSA-111933,Calmodulin induced events,1/249,33/8183,0.640046452536131,0.800836079996585,0.668273358273671,CAMK2B,1
R-HSA-111997,R-HSA-111997,CaM pathway,1/249,33/8183,0.640046452536131,0.800836079996585,0.668273358273671,CAMK2B,1
R-HSA-113418,R-HSA-113418,Formation of the Early Elongation Complex,1/249,33/8183,0.640046452536131,0.800836079996585,0.668273358273671,POLR2H,1
R-HSA-167158,R-HSA-167158,Formation of the HIV-1 Early Elongation Complex,1/249,33/8183,0.640046452536131,0.800836079996585,0.668273358273671,POLR2H,1
R-HSA-445355,R-HSA-445355,Smooth Muscle Contraction,1/249,33/8183,0.640046452536131,0.800836079996585,0.668273358273671,MYL6,1
R-HSA-9022692,R-HSA-9022692,Regulation of MECP2 expression and activity,1/249,33/8183,0.640046452536131,0.800836079996585,0.668273358273671,CAMK2B,1
R-HSA-1296071,R-HSA-1296071,Potassium Channels,2/249,71/8183,0.641392151167773,0.801221263271069,0.668594782004219,GNG2/GNB2,2
R-HSA-5689880,R-HSA-5689880,Ub-specific processing proteases,5/249,180/8183,0.645062689569286,0.804504679075103,0.671334692656072,HIST1H2AC/PSMB9/PSMB8/PSMD7/PSMD6,5
R-HSA-199992,R-HSA-199992,trans-Golgi Network Vesicle Budding,2/249,72/8183,0.648980186107835,0.805458042431319,0.672130245388556,VAMP8/FTH1,2
R-HSA-111996,R-HSA-111996,Ca-dependent events,1/249,34/8183,0.651043806317542,0.805458042431319,0.672130245388556,CAMK2B,1
R-HSA-5655253,R-HSA-5655253,Signaling by FGFR2 in disease,1/249,34/8183,0.651043806317542,0.805458042431319,0.672130245388556,POLR2H,1
R-HSA-6788656,R-HSA-6788656,Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism,1/249,34/8183,0.651043806317542,0.805458042431319,0.672130245388556,PCBD1,1
R-HSA-6806667,R-HSA-6806667,Metabolism of fat-soluble vitamins,1/249,34/8183,0.651043806317542,0.805458042431319,0.672130245388556,RBP1,1
R-HSA-187037,R-HSA-187037,Signaling by NTRK1 (TRKA),2/249,73/8183,0.656440765788955,0.806962215269225,0.673385431885418,RHOA/AP2M1,2
R-HSA-446728,R-HSA-446728,Cell junction organization,2/249,73/8183,0.656440765788955,0.806962215269225,0.673385431885418,CLDN18/CDH18,2
R-HSA-8852135,R-HSA-8852135,Protein ubiquitination,2/249,73/8183,0.656440765788955,0.806962215269225,0.673385431885418,HLA-A/PRKDC,2
R-HSA-8936459,R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,2/249,73/8183,0.656440765788955,0.806962215269225,0.673385431885418,HIST1H4C/HIST1H2AC,2
R-HSA-176033,R-HSA-176033,Interactions of Vpr with host cellular proteins,1/249,35/8183,0.661706475629965,0.809780720766421,0.675737389022429,SLC25A6,1
R-HSA-432720,R-HSA-432720,Lysosome Vesicle Biogenesis,1/249,35/8183,0.661706475629965,0.809780720766421,0.675737389022429,VAMP8,1
R-HSA-69618,R-HSA-69618,Mitotic Spindle Checkpoint,3/249,111/8183,0.661880355963227,0.809780720766421,0.675737389022429,RPS27/MAD1L1/DYNLL1,3
R-HSA-5688426,R-HSA-5688426,Deubiquitination,7/249,255/8183,0.663477946500676,0.810450909333105,0.676296641003354,UCHL1/RHOA/HIST1H2AC/PSMB9/PSMB8/PSMD7/PSMD6,7
R-HSA-3214815,R-HSA-3214815,HDACs deacetylate histones,2/249,75/8183,0.670982424678047,0.81192243498656,0.677524584417473,HIST1H4C/HIST1H2AC,2
R-HSA-111465,R-HSA-111465,Apoptotic cleavage of cellular proteins,1/249,36/8183,0.672044606161155,0.81192243498656,0.677524584417473,DSP,1
R-HSA-5689896,R-HSA-5689896,Ovarian tumor domain proteases,1/249,36/8183,0.672044606161155,0.81192243498656,0.677524584417473,RHOA,1
R-HSA-6804757,R-HSA-6804757,Regulation of TP53 Degradation,1/249,36/8183,0.672044606161155,0.81192243498656,0.677524584417473,SGK1,1
R-HSA-6806003,R-HSA-6806003,Regulation of TP53 Expression and Degradation,1/249,36/8183,0.672044606161155,0.81192243498656,0.677524584417473,SGK1,1
R-HSA-76046,R-HSA-76046,RNA Polymerase III Transcription Initiation,1/249,36/8183,0.672044606161155,0.81192243498656,0.677524584417473,POLR2H,1
R-HSA-8853659,R-HSA-8853659,RET signaling,1/249,36/8183,0.672044606161155,0.81192243498656,0.677524584417473,RET,1
R-HSA-211000,R-HSA-211000,Gene Silencing by RNA,3/249,113/8183,0.673722968485886,0.8126783307361,0.678155356436451,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-397014,R-HSA-397014,Muscle contraction,4/249,150/8183,0.674807700435314,0.812716918464995,0.678187556722903,MYL6/CACNA2D1/CAMK2B/NPPA,4
R-HSA-3769402,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,1/249,37/8183,0.682068037248165,0.820181502734554,0.684416525325262,SOX4,1
R-HSA-1169410,R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,2/249,77/8183,0.685023581929664,0.821177337344256,0.685247519027386,EIF4A2/EIF4A1,2
R-HSA-6805567,R-HSA-6805567,Keratinization,2/249,77/8183,0.685023581929664,0.821177337344256,0.685247519027386,KRT12/DSP,2
R-HSA-3560782,R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,1/249,38/8183,0.691786311091181,0.822981475932243,0.686753017821834,HEXB,1
R-HSA-5696394,R-HSA-5696394,DNA Damage Recognition in GG-NER,1/249,38/8183,0.691786311091181,0.822981475932243,0.686753017821834,RBX1,1
R-HSA-428157,R-HSA-428157,Sphingolipid metabolism,2/249,78/8183,0.691858779637339,0.822981475932243,0.686753017821834,PSAP/HEXB,2
R-HSA-6781827,R-HSA-6781827,Transcription-Coupled Nucleotide Excision Repair (TC-NER),2/249,78/8183,0.691858779637339,0.822981475932243,0.686753017821834,RBX1/POLR2H,2
R-HSA-6811558,R-HSA-6811558,PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling,2/249,78/8183,0.691858779637339,0.822981475932243,0.686753017821834,HGF/RAC1,2
R-HSA-112310,R-HSA-112310,Neurotransmitter release cycle,1/249,39/8183,0.70120868169134,0.830265494272569,0.692831309646594,SYT1,1
R-HSA-1236394,R-HSA-1236394,Signaling by ERBB4,1/249,39/8183,0.70120868169134,0.830265494272569,0.692831309646594,NCSTN,1
R-HSA-1489509,R-HSA-1489509,DAG and IP3 signaling,1/249,39/8183,0.70120868169134,0.830265494272569,0.692831309646594,CAMK2B,1
R-HSA-168253,R-HSA-168253,Host Interactions with Influenza Factors,1/249,40/8183,0.710344123520768,0.837469462018451,0.698842801684336,SLC25A6,1
R-HSA-168142,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,2/249,81/8183,0.711635292913255,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-168176,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,2/249,81/8183,0.711635292913255,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-975871,R-HSA-975871,MyD88 cascade initiated on plasma membrane,2/249,81/8183,0.711635292913255,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-2672351,R-HSA-2672351,Stimuli-sensing channels,2/249,82/8183,0.717988182205342,0.837469462018451,0.698842801684336,SGK1/ANO10,2
R-HSA-1433557,R-HSA-1433557,Signaling by SCF-KIT,1/249,41/8183,0.719201339932818,0.837469462018451,0.698842801684336,RAC1,1
R-HSA-1442490,R-HSA-1442490,Collagen degradation,1/249,41/8183,0.719201339932818,0.837469462018451,0.698842801684336,CTSL,1
R-HSA-5696400,R-HSA-5696400,Dual Incision in GG-NER,1/249,41/8183,0.719201339932818,0.837469462018451,0.698842801684336,RBX1,1
R-HSA-74158,R-HSA-74158,RNA Polymerase III Transcription,1/249,41/8183,0.719201339932818,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-749476,R-HSA-749476,RNA Polymerase III Abortive And Retractive Initiation,1/249,41/8183,0.719201339932818,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-3700989,R-HSA-3700989,Transcriptional Regulation by TP53,9/249,344/8183,0.726563789334764,0.837469462018451,0.698842801684336,FOS/COX4I1/SGK1/CDKN1A/YWHAH/COX6C/POLR2H/YWHAG/JUN,9
R-HSA-167169,R-HSA-167169,HIV Transcription Elongation,1/249,42/8183,0.727788771320282,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-167200,R-HSA-167200,Formation of HIV-1 elongation complex containing HIV-1 Tat,1/249,42/8183,0.727788771320282,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-167246,R-HSA-167246,Tat-mediated elongation of the HIV-1 transcript,1/249,42/8183,0.727788771320282,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-168325,R-HSA-168325,Viral Messenger RNA Synthesis,1/249,42/8183,0.727788771320282,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-3214842,R-HSA-3214842,HDMs demethylate histones,1/249,42/8183,0.727788771320282,0.837469462018451,0.698842801684336,HIST1H4C,1
R-HSA-6782315,R-HSA-6782315,tRNA modification in the nucleus and cytosol,1/249,42/8183,0.727788771320282,0.837469462018451,0.698842801684336,TRIT1,1
R-HSA-975138,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,2/249,84/8183,0.730342224205774,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-2173793,R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,1/249,43/8183,0.736114603029071,0.837469462018451,0.698842801684336,JUNB,1
R-HSA-5696395,R-HSA-5696395,Formation of Incision Complex in GG-NER,1/249,43/8183,0.736114603029071,0.837469462018451,0.698842801684336,RBX1,1
R-HSA-6802946,R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,1/249,43/8183,0.736114603029071,0.837469462018451,0.698842801684336,CAMK2B,1
R-HSA-6802955,R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,1/249,43/8183,0.736114603029071,0.837469462018451,0.698842801684336,CAMK2B,1
R-HSA-168181,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,2/249,85/8183,0.736345900800722,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-199418,R-HSA-199418,Negative regulation of the PI3K/AKT network,2/249,85/8183,0.736345900800722,0.837469462018451,0.698842801684336,HGF/RAC1,2
R-HSA-8876198,R-HSA-8876198,RAB GEFs exchange GTP for GDP on RABs,2/249,85/8183,0.736345900800722,0.837469462018451,0.698842801684336,RAB13/RAB7A,2
R-HSA-975155,R-HSA-975155,MyD88 dependent cascade initiated on endosome,2/249,85/8183,0.736345900800722,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-167152,R-HSA-167152,Formation of HIV elongation complex in the absence of HIV Tat,1/249,44/8183,0.744186773034692,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-5578775,R-HSA-5578775,Ion homeostasis,1/249,44/8183,0.744186773034692,0.837469462018451,0.698842801684336,CAMK2B,1
R-HSA-69231,R-HSA-69231,Cyclin D associated events in G1,1/249,44/8183,0.744186773034692,0.837469462018451,0.698842801684336,CDKN1A,1
R-HSA-69236,R-HSA-69236,G1 Phase,1/249,44/8183,0.744186773034692,0.837469462018451,0.698842801684336,CDKN1A,1
R-HSA-1592230,R-HSA-1592230,Mitochondrial biogenesis,2/249,87/8183,0.748013106076332,0.837469462018451,0.698842801684336,ATP5F1E/ATP5ME,2
R-HSA-5368286,R-HSA-5368286,Mitochondrial translation initiation,2/249,87/8183,0.748013106076332,0.837469462018451,0.698842801684336,MRPL33/MRPS24,2
R-HSA-5389840,R-HSA-5389840,Mitochondrial translation elongation,2/249,87/8183,0.748013106076332,0.837469462018451,0.698842801684336,MRPL33/MRPS24,2
R-HSA-5419276,R-HSA-5419276,Mitochondrial translation termination,2/249,87/8183,0.748013106076332,0.837469462018451,0.698842801684336,MRPL33/MRPS24,2
R-HSA-167161,R-HSA-167161,HIV Transcription Initiation,1/249,45/8183,0.752012979388589,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-167162,R-HSA-167162,RNA Polymerase II HIV Promoter Escape,1/249,45/8183,0.752012979388589,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-2022090,R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,1/249,45/8183,0.752012979388589,0.837469462018451,0.698842801684336,CTSL,1
R-HSA-73776,R-HSA-73776,RNA Polymerase II Promoter Escape,1/249,45/8183,0.752012979388589,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-73779,R-HSA-73779,RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,1/249,45/8183,0.752012979388589,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-75953,R-HSA-75953,RNA Polymerase II Transcription Initiation,1/249,45/8183,0.752012979388589,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-76042,R-HSA-76042,RNA Polymerase II Transcription Initiation And Promoter Clearance,1/249,45/8183,0.752012979388589,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-212165,R-HSA-212165,Epigenetic regulation of gene expression,3/249,128/8183,0.752883670354753,0.837469462018451,0.698842801684336,HIST1H4C/HIST1H2AC/POLR2H,3
R-HSA-73894,R-HSA-73894,DNA Repair,8/249,318/8183,0.758523263368766,0.837469462018451,0.698842801684336,TERF2IP/HIST1H4C/HIST1H2AC/BPHL/RBX1/NTHL1/POLR2H/PRKDC,8
R-HSA-166058,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,2/249,89/8183,0.75923580603203,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-168138,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,2/249,89/8183,0.75923580603203,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-168188,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,2/249,89/8183,0.75923580603203,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-177929,R-HSA-177929,Signaling by EGFR,1/249,46/8183,0.759600687441211,0.837469462018451,0.698842801684336,CDC42,1
R-HSA-168164,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,2/249,90/8183,0.76468393219583,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-168179,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,2/249,90/8183,0.76468393219583,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-181438,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,2/249,90/8183,0.76468393219583,0.837469462018451,0.698842801684336,FOS/JUN,2
R-HSA-1227986,R-HSA-1227986,Signaling by ERBB2,1/249,47/8183,0.766957136848504,0.837469462018451,0.698842801684336,RHOA,1
R-HSA-1793185,R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,1/249,47/8183,0.766957136848504,0.837469462018451,0.698842801684336,HEXB,1
R-HSA-2122947,R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,1/249,47/8183,0.766957136848504,0.837469462018451,0.698842801684336,RBX1,1
R-HSA-73762,R-HSA-73762,RNA Polymerase I Transcription Initiation,1/249,47/8183,0.766957136848504,0.837469462018451,0.698842801684336,POLR2H,1
R-HSA-936837,R-HSA-936837,Ion transport by P-type ATPases,1/249,47/8183,0.766957136848504,0.837469462018451,0.698842801684336,CAMK2B,1
R-HSA-112043,R-HSA-112043,PLC beta mediated events,1/249,48/8183,0.774089348368258,0.840502077271864,0.701373426902619,CAMK2B,1
R-HSA-1650814,R-HSA-1650814,Collagen biosynthesis and modifying enzymes,1/249,48/8183,0.774089348368258,0.840502077271864,0.701373426902619,PPIB,1
R-HSA-6791312,R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,1/249,48/8183,0.774089348368258,0.840502077271864,0.701373426902619,CDKN1A,1
R-HSA-73893,R-HSA-73893,DNA Damage Bypass,1/249,48/8183,0.774089348368258,0.840502077271864,0.701373426902619,RBX1,1
R-HSA-163685,R-HSA-163685,Integration of energy metabolism,2/249,92/8183,0.775260822533992,0.840591790725059,0.701448290051453,GNG2/GNB2,2
R-HSA-5368287,R-HSA-5368287,Mitochondrial translation,2/249,93/8183,0.780392462724758,0.844447043010399,0.704665380859509,MRPL33/MRPS24,2
R-HSA-112040,R-HSA-112040,G-protein mediated events,1/249,49/8183,0.781004130452623,0.844447043010399,0.704665380859509,CAMK2B,1
R-HSA-425407,R-HSA-425407,SLC-mediated transmembrane transport,4/249,175/8183,0.785120543525708,0.845670013125454,0.705685912234494,APOD/BSG/SLC25A6/LCN15,4
R-HSA-166166,R-HSA-166166,MyD88-independent TLR4 cascade ,2/249,94/8183,0.785421501827656,0.845670013125454,0.705685912234494,FOS/JUN,2
R-HSA-937061,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling ,2/249,94/8183,0.785421501827656,0.845670013125454,0.705685912234494,FOS/JUN,2
R-HSA-6794361,R-HSA-6794361,Neurexins and neuroligins,1/249,50/8183,0.787708085642848,0.8469507550366,0.706754652416689,SYT1,1
R-HSA-8951664,R-HSA-8951664,Neddylation,5/249,220/8183,0.805326427466495,0.864689849797127,0.721557387613638,PSMB9/PSMB8/RBX1/PSMD7/PSMD6,5
R-HSA-193648,R-HSA-193648,NRAGE signals death through JNK,1/249,53/8183,0.80661805556137,0.86487380401858,0.721710891818068,RAC1,1
R-HSA-1226099,R-HSA-1226099,Signaling by FGFR in disease,1/249,54/8183,0.812540823601372,0.868810963739971,0.724996331891004,POLR2H,1
R-HSA-425366,R-HSA-425366,Transport of bile salts and organic acids, metal ions and amine compounds,1/249,54/8183,0.812540823601372,0.868810963739971,0.724996331891004,BSG,1
R-HSA-6802949,R-HSA-6802949,Signaling by RAS mutants,1/249,55/8183,0.818282899493027,0.873740523386745,0.729109899526436,CAMK2B,1
R-HSA-112382,R-HSA-112382,Formation of RNA Pol II elongation complex ,1/249,57/8183,0.829246772676634,0.881788579209865,0.735825757399015,POLR2H,1
R-HSA-72187,R-HSA-72187,mRNA 3'-end processing,1/249,57/8183,0.829246772676634,0.881788579209865,0.735825757399015,THOC7,1
R-HSA-75955,R-HSA-75955,RNA Polymerase II Transcription Elongation,1/249,57/8183,0.829246772676634,0.881788579209865,0.735825757399015,POLR2H,1
R-HSA-163125,R-HSA-163125,Post-translational modification: synthesis of GPI-anchored proteins,1/249,60/8183,0.844469369045393,0.896740512934035,0.748302691458453,NRN1,1
R-HSA-211945,R-HSA-211945,Phase I - Functionalization of compounds,1/249,61/8183,0.849236958249837,0.900564466715486,0.751493664616686,BPHL,1
R-HSA-5696398,R-HSA-5696398,Nucleotide Excision Repair,2/249,110/8183,0.853131918485438,0.902985104859176,0.753513613544881,RBX1/POLR2H,2
R-HSA-3214841,R-HSA-3214841,PKMTs methylate histone lysines,1/249,62/8183,0.853858972211397,0.902985104859176,0.753513613544881,HIST1H4C,1
R-HSA-5654738,R-HSA-5654738,Signaling by FGFR2,1/249,63/8183,0.858339838597231,0.90524365491402,0.755398304891438,POLR2H,1
R-HSA-6802952,R-HSA-6802952,Signaling by BRAF and RAF fusions,1/249,63/8183,0.858339838597231,0.90524365491402,0.755398304891438,CAMK2B,1
R-HSA-204005,R-HSA-204005,COPII-mediated vesicle transport,1/249,65/8183,0.866895172664719,0.910534793601583,0.759813599242117,FOLR1,1
R-HSA-2187338,R-HSA-2187338,Visual phototransduction,1/249,65/8183,0.866895172664719,0.910534793601583,0.759813599242117,RBP1,1
R-HSA-5693565,R-HSA-5693565,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,1/249,65/8183,0.866895172664719,0.910534793601583,0.759813599242117,HIST1H4C,1
R-HSA-166016,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,2/249,115/8183,0.869927123593392,0.912340425096077,0.761320343821652,FOS/JUN,2
R-HSA-5693606,R-HSA-5693606,DNA Double Strand Break Response,1/249,66/8183,0.870977841056747,0.912340425096077,0.761320343821652,HIST1H4C,1
R-HSA-156580,R-HSA-156580,Phase II - Conjugation of compounds,1/249,67/8183,0.874935771028026,0.912770831396806,0.761679504792535,GGCT,1
R-HSA-167172,R-HSA-167172,Transcription of the HIV genome,1/249,67/8183,0.874935771028026,0.912770831396806,0.761679504792535,POLR2H,1
R-HSA-4551638,R-HSA-4551638,SUMOylation of chromatin organization proteins,1/249,67/8183,0.874935771028026,0.912770831396806,0.761679504792535,HIST1H4C,1
R-HSA-983168,R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,6/249,290/8183,0.881506120215322,0.918384244003008,0.766363726929153,PSMB9/PSMB8/MYLIP/RBX1/PSMD7/PSMD6,6
R-HSA-68875,R-HSA-68875,Mitotic Prophase,2/249,120/8183,0.884946289497491,0.920295578673005,0.767958677594599,HIST1H4C/HIST1H2AC,2
R-HSA-3214847,R-HSA-3214847,HATs acetylate histones,2/249,121/8183,0.887751416287155,0.920295578673005,0.767958677594599,HIST1H4C/HIST1H2AC,2
R-HSA-3108232,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,3/249,167/8183,0.888336622151038,0.920295578673005,0.767958677594599,HIST1H4C/PARK7/DDX17,3
R-HSA-71387,R-HSA-71387,Metabolism of carbohydrates,5/249,253/8183,0.889292667264771,0.920295578673005,0.767958677594599,PGAM2/AKR1B1/MDH2/HEXB/ALDOA,5
R-HSA-159236,R-HSA-159236,Transport of Mature mRNA derived from an Intron-Containing Transcript,1/249,71/8183,0.889594326304011,0.920295578673005,0.767958677594599,THOC7,1
R-HSA-8957322,R-HSA-8957322,Metabolism of steroids,2/249,122/8183,0.890493260710796,0.920295578673005,0.767958677594599,TSPO/AKR1B1,2
R-HSA-6807505,R-HSA-6807505,RNA polymerase II transcribes snRNA genes,1/249,74/8183,0.899453419322189,0.928312887321831,0.774648877885139,POLR2H,1
R-HSA-2990846,R-HSA-2990846,SUMOylation,3/249,173/8183,0.901930332048844,0.92962645706503,0.775745011895008,HIST1H4C/PARK7/DDX17,3
R-HSA-190236,R-HSA-190236,Signaling by FGFR,1/249,76/8183,0.905533875132396,0.932096202136279,0.777805939061089,POLR2H,1
R-HSA-674695,R-HSA-674695,RNA Polymerase II Pre-transcription Events,1/249,78/8183,0.911248008783701,0.935483328166246,0.780632392743036,POLR2H,1
R-HSA-6802957,R-HSA-6802957,Oncogenic MAPK signaling,1/249,78/8183,0.911248008783701,0.935483328166246,0.780632392743036,CAMK2B,1
R-HSA-211859,R-HSA-211859,Biological oxidations,2/249,132/8183,0.91469456885938,0.937774511499922,0.78254431556852,GGCT/BPHL,2
R-HSA-72202,R-HSA-72202,Transport of Mature Transcript to Cytoplasm,1/249,80/8183,0.916617806033476,0.938499928723931,0.783149654184682,THOC7,1
R-HSA-5696399,R-HSA-5696399,Global Genome Nucleotide Excision Repair (GG-NER),1/249,84/8183,0.926405840102879,0.947265309350229,0.790464097794301,RBX1,1
R-HSA-5693607,R-HSA-5693607,Processing of DNA double-strand break ends,1/249,88/8183,0.935048950239254,0.954029862395445,0.796108911625324,HIST1H4C,1
R-HSA-8978868,R-HSA-8978868,Fatty acid metabolism,2/249,143/8183,0.935493012737502,0.954029862395445,0.796108911625324,PON3/PON2,2
R-HSA-196854,R-HSA-196854,Metabolism of vitamins and cofactors,2/249,155/8183,0.952683553418701,0.969000926533909,0.808601809433805,CYB5A/RBP1,2
R-HSA-5693532,R-HSA-5693532,DNA Double-Strand Break Repair,2/249,155/8183,0.952683553418701,0.969000926533909,0.808601809433805,HIST1H4C/PRKDC,2
R-HSA-196849,R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,1/249,103/8183,0.959366994902596,0.973225726239489,0.812127276327471,CYB5A,1
R-HSA-1483206,R-HSA-1483206,Glycerophospholipid biosynthesis,1/249,104/8183,0.960619175381464,0.973225726239489,0.812127276327471,MFSD2A,1
R-HSA-72306,R-HSA-72306,tRNA processing,1/249,104/8183,0.960619175381464,0.973225726239489,0.812127276327471,TRIT1,1
R-HSA-1630316,R-HSA-1630316,Glycosaminoglycan metabolism,1/249,109/8183,0.966326483312549,0.977724829773641,0.815881641425509,HEXB,1
R-HSA-5693567,R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),1/249,122/8183,0.977597440389973,0.987470911751376,0.824014450493376,HIST1H4C,1
R-HSA-3781865,R-HSA-3781865,Diseases of glycosylation,1/249,124/8183,0.978960154273325,0.987470911751376,0.824014450493376,HEXB,1
R-HSA-5693538,R-HSA-5693538,Homology Directed Repair,1/249,128/8183,0.981442829765535,0.987470911751376,0.824014450493376,HIST1H4C,1
R-HSA-3247509,R-HSA-3247509,Chromatin modifying enzymes,3/249,249/8183,0.983321015798367,0.987470911751376,0.824014450493376,HIST1H4C/HIST1H2AC/RPS2,3
R-HSA-4839726,R-HSA-4839726,Chromatin organization,3/249,249/8183,0.983321015798367,0.987470911751376,0.824014450493376,HIST1H4C/HIST1H2AC/RPS2,3
R-HSA-162599,R-HSA-162599,Late Phase of HIV Life Cycle,1/249,132/8183,0.983633589555451,0.987470911751376,0.824014450493376,POLR2H,1
R-HSA-162587,R-HSA-162587,HIV Life Cycle,1/249,143/8183,0.98841820215329,0.990985522158883,0.826947286012048,POLR2H,1
R-HSA-5633007,R-HSA-5633007,Regulation of TP53 Activity,1/249,153/8183,0.991545853149654,0.992831904839861,0.82848803621761,SGK1,1
R-HSA-1483257,R-HSA-1483257,Phospholipid metabolism,1/249,177/8183,0.996034773188804,0.996034773188804,0.831160732467341,MFSD2A,1
